

**In vitro Characterization of SLK-deficient Mouse Embryonic Fibroblasts (MEFs)**

**Clinton Royce Cunha**

Thesis submitted to the Faculty of Graduate and Postdoctoral Studies in partial fulfillment of the  
Requirements for the Masters of Science degree in Cellular and Molecular Medicine

Department of Cellular and Molecular Medicine

Faculty of Medicine

University of Ottawa, Ontario, Canada

© Clinton Royce Cunha, Ottawa, Canada, 2019

## **Abstract**

The Ste20-like kinase (SLK) has been shown to be expressed in all cell lines and tissues. Previous studies using siRNA and dominant negative approaches have established that SLK plays important roles in cell growth, cytoskeletal dynamics and cell migration. However, the SLK-dependent signaling mechanisms have yet to be elucidated. To further investigate the role of SLK in those processes, we have assessed the effect of a genetic deletion of SLK on cell growth, apoptosis and cell motility. Conditional SLK-floxed fibroblasts were derived and the SLK gene was inactivated in established cell lines. Using cell counts and flow cytometry, we show that SLK deletion does not affect cell growth or progression through the cell cycle. Similarly, Boyden chamber migration assay showed that SLK deletion did not affect cell motility. Using a scratch wound assays and immunofluorescence, we assessed the localization of cytoskeletal protein during migration. Our data show that Paxillin and FAK are still recruited to the leading edge of migrating cells in the absence of SLK. However, nocodazole release studies show that SLK-deficient cells have a faster focal adhesion turnover rate. As SLK has been shown to play a role in apoptosis, we tested the effect of SLK deletion on cell death. Using multiple apoptotic triggers, we show that SLK deletion does not affect apoptosis in fibroblasts and that signaling downstream of those triggers is unchanged. Overall, in contrast to siRNA studies, our data show that the genetic deletion of SLK doesn't affect cell growth, apoptosis or cell migration. This is likely due to the activation of compensatory mechanisms, bypassing the requirements for SLK.

<b>Abstract.....</b>	<b>ii</b>
<b>Table of Contents.....</b>	<b>iii</b>
<b>List of Figures.....</b>	<b>vi</b>
<b>Abbreviations.....</b>	<b>vii</b>
<b>Acknowledgements.....</b>	<b>xiii</b>
<b>1. Introduction.....</b>	<b>1</b>
1.1 The Ste20-like Kinase SLK.....	1
1.2 SLK and Cell Cycle Control.....	6
1.3 SLK and Cell Migration.....	10
1.4 SLK and Apoptosis.....	15
1.5 Rationale and Hypothesis.....	19
1.6 Objectives.....	19
<b>2. Materials and Methods.....</b>	<b>20</b>
2.1 Cell Culture .....	20
2.2 Western Blots and Protein Preparation.....	20
2.3 Transfections.....	21
2.4 Proliferation Assay.....	21
2.5 Flow Cytometry.....	22
2.6 Boyden Chamber Migration Assay.....	22
2.7 Alamar Blue Apoptosis Assay.....	23

2.8 Immunofluorescence.....	23
2.9 Immunoprecipitation.....	24
2.10 In-vitro binding assay.....	24
<b>3. Results.....</b>	<b>26</b>
3.1 Generation of SLK-deficient Fibroblasts.....	26
3.2 SLK deletion in MEFs does not impair proliferation in vitro.....	29
3.3 SLK Deletion does not impair cell Migration .....	34
3.4 SLK deletion enhances Nocodazole washout-induced focal adhesion turnover...37	
3.5 SLK is not required for programmed cell death.....	44
<b>4. Discussion.....</b>	<b>54</b>
4.1 SLK is not required for the growth of Mouse Embryonic Fibroblasts in vitro.....	54
4.2 SLK is not required for the migration of Mouse Embryonic Fibroblasts.....	55
4.3 The Apoptotic Response is not affected in SLK-deficient MEFs.....	57
4.4 Future Directions.....	59
4.5 Physiological Relevance.....	60
<b>5. Conclusion.....</b>	<b>60</b>
<b>6. Appendix I - Validate the putative interaction between SLK and RASSF1A .....</b>	<b>62</b>
6.1 Introduction to Melanoma.....	62
6.1.1 The RASSF1A tumor suppressor.....	64
6.2 Purpose of Research.....	65

6.2.1 Rationale and Hypothesis.....	65
6.2.2 Objectives.....	65
6.3 Results.....	66
6.3.1 SLK does not interact with RASSF1A in a specific manner.....	66
6.4 Discussion.....	71
<b>References.....</b>	<b>72</b>

## **List of Figures**

<b>Figure 1:</b> Schematic of the murine SLK structure.....	18
<b>Figure 2:</b> SLK and cell cycle control.....	22
<b>Figure 3:</b> Mechanisms of SLK recruitment and activation during cell migration.....	27
<b>Figure 4:</b> Generation of SLK-deficient Fibroblasts.....	40
<b>Figure 5 –</b> SLK deletion in MEFs does not impair proliferation in vitro.....	44
<b>Figure 6 –</b> SLK deletion does not impair cell cycle progression.....	46
<b>Figure 7 –</b> SLK deletion does not impair cell migration.....	49
<b>Figure 8 –</b> SLK deletion enhances Nocodazole washout-induced focal adhesion turnover.....	52
<b>Figure 9 –</b> SLK deletion does not alter focal adhesion size.....	54
<b>Figure 10 –</b> SLK is not required for Paxillin localization at the leading edge.....	56
<b>Figure 11 –</b> SLK is not required for programmed cell death.....	60
<b>Figure 12 –</b> SLK deletion does not affect PARP breakdown or Caspase 3 activation.....	62
<b>Figure 13 –</b> Apoptotic signaling in SLK-null cells.....	64
<b>Figure 14 –</b> Apoptotic signaling in Neu-transformed SLK-null cells.....	66
<b>Figure 15 -</b> The SLK-RASSF1A interaction is non-specific.....	81
<b>Figure 16 -</b> RASSF1A and SLK do not interact in vivo.....	83

## Abbreviations

A375	Human Melanoma Line
AdCre	Adenovirus expressing Cre recombinase
AdGFP	Adenovirus expressing Green Fluorescent Protein
AKT	Protein Kinase B (PKB)
ASK1	Apoptosis signal-regulating kinase-1
ATH	ATI-46 Protein (motif) Domain
BRAF	Proto-oncogene (the v-raf murine sarcoma viral oncogene homolog B1)
BSA	Bovine Serum Albumin
C2C12	Immortalized Mouse Myoblast Line
CAD	Caspase-activated DNase
CDK	Cyclin Dependent Kinase
CDK4	Cyclin-dependent kinase 4
CDKN2A	Cyclin Dependent Kinase Inhibitor 2A
cDNA	Complementary DNA
CK	Casein Kinase II
c-KIT	Proto-oncogene that encodes the KIT protein

CpG	Cytosine phosphodiester bonded to a Guanine
CRISPR	Clustered Regularly Interspaced Short Palindromic Repeats
DAPI	(4, 6-diamidino-2-phenylindole)
DIABLO	Direct IAP-Binding protein with Low PI
DISC	Death-Inducing Complex
DMEM	Dulbecco's Modified Eagle's Medium
ECM	Extracellular Matrix
EDTA	Ethylenediamine tetraacetic acid
EGFR	Epidermal Growth Factor Receptor
ELK-1	ETS transcription Factor
ERK	Extracellular Signal-Regulated Kinase
FADD	Fas Associated Via Death Domain
FAK	Focal Adhesion Kinase
FasL	Fas Ligand
FasR	Fas Receptor
FBS	Fetal Bovine Serum
G proteins	Guanine nucleotide-binding proteins
G2-M	Gap 2/Mitosis



GCK	Germinal Center Kinase
H&E	Hematoxylin and Eosin
Her2/Neu	ERBB2, Epidermal growth factor receptor 2
HSF1	Heat Shock Factor 1
HSP70	Heat Shock Protein 70
HtrA2	HtrA Serine Peptidase 2/Omi
ICAD	(CAD inhibitor) See CAD
JNK1	c-Jun N-terminal kinase-1
LacZ	Gene Reporter
LDB1/2	LIM domain-binding protein 1/2
LMO4	LIM Domain Only 4
LOK	Lymph Oriented Kinase
MAP4K	Mitogen-activated protein kinase kinase kinase kinase
MAPK	Mitogen-activated protein kinase
MEK	MAPK/ERK kinase
MITF	Melanocyte inducing transcription factor
MST1	Macrophage Stimulating 1
p14 <sup>ARF</sup>	ARF tumor suppressor

p16 <sup>INK4a</sup>	Tumor suppressor that inhibits Cyclin D-dependent protein kinases
p38	Mitogen activated protein kinase p38
p53	Tumor protein 53
PAK	p21-activated kinase
PARP	Poly (ADP-ribose) polymerase
PBS	Phosphate Buffered Saline
PDGFR	Platelet derived growth factor receptor
PEI	Polyethylenimine
PFA	Paraformaldehyde
pFAK	Phospho-Focal Adhesion Kinase
Phospho-RB	Phospho-Retinoblastoma Protein
PI	Propidium Iodide
PI3K	phosphoinositide (PI) 3-Kinase
p-JNK	Phospho- c-Jun N-terminal kinase-1
PLK1	Polo-like Kinase 1
P-P38	Phospho-Mitogen activated protein kinase p38
PTEN	Phosphatase and tensin homolog
PVDF	Polyvinylidene difluoride membrane

RA	RAS association (protein domain)
RASSF1A	Ras association domain family 1 isoform A
RB	Retinoblastoma
RIPA	Radioimmunoprecipitation assay buffer
Rpm	Revolutions per minute
SARAH	Sav/Rassf/Hpo domain
SH2	SRC homology 2 domain
SH3	SRC homology 3 domain
SLK	Ste-20 like Kinase
Smac	Second Mitochondria-derived Activator of Caspases
SOX10	SRY-Box10
Src	Steroid receptor co-activator
Ste20p	Ste 20 protein
TBST	Tris-buffered Saline, 0.1% Tween
TNF- $\alpha$	Tumor Necrosis Factor - $\alpha$
TNF	Tumor Necrosis Factor
TNFR1	Tumor Necrosis Factor Receptor 1
TPR	Translocated Promoter Region

TRADD	TNFR Associated Via Death Domain
v-Src	Viral Src Proto-oncogene
xPlkk1	Xenopus polo-like kinase 1
$\Delta$ 3-6	Delta 3-6, SLK region in this context

## **Acknowledgements**

I would like to thank Dr. Luc Sabourin for allowing me to work in his lab and allowing me to present research from his lab at the AEK international Cancer Congress 2019 in Heidelberg, Germany. Thank you for taking a chance and investing your time and effort into my career growth. I would also like to thank Dr. Khalid Al-Zahrani for the patience and willingness to teach me techniques (Binding Assay, Proliferation Assay, Western blot and almost all of my techniques). He constantly pushed me to work harder and challenge myself. I would like to thank Dr. Benjamin Pryce for taking the time to teach me immunoprecipitations, Immunofluorescence and other techniques. His persistence in the lab was inspiring for a fresh graduate student. Cédrik Labrèche was instrumental at keeping lab supplies available for daily use. John Abou-Hamad helped with some techniques and was always available in the case of emergencies. Michele Ardolino helped me with all my Flow Cytometry experiments. Jonathon Hodgins also helped me with some Flow Cytometry experiments. Thank you Christina Addison for reviewing my thesis and giving me constructive feedback. Thank you to the Ottawa Hospital Research institute (OHRI) for acknowledging my research at the 2018 OHRI research day. Thank you to the University of Ottawa (UOttawa) for accepting me into this program and allowing me to compete in your UOttawa Three Minute Thesis Final. I would like to thank my loving parents (Cyril and Charlotte Cunha) for taking care of me throughout my life and trying their best to be as supportive as possible.

## **1. INTRODUCTION**

### **1.1 The Ste20-like Kinase SLK**

The archetype Sterile 20 protein (Ste20p) plays a role in the yeast mitogen-activated protein kinase kinase kinase kinase (MAP4K) mating pathway (Dan I, Watanabe NM, Kusumi A., 2001). There are several homologs in different species and those are divided into the p21-activated kinase (PAK) and germinal center kinase (GCK) families. Their modular structure allows them to crosstalk with several regulatory proteins and signaling molecules that are involved in multiple biological processes (Dan I, Watanabe NM, Kusumi A., 2001). They play critical roles in morphogenesis, cytoskeletal dynamics and apoptosis. The Ste20-like kinase SLK was first identified and cloned from the guinea pig (Itoh et al, 1997). The mouse and human homologs were subsequently isolated and characterized (Sabourin et al, 1999, Yamada et al, 2000). A yeast two-hybrid screen was used to isolate murine SLK (Sabourin and Rudnicki 1999). Using a muscle specific transactivator as the bait protein, SLK was isolated as a false positive clone from a skeletal muscle cDNA library. Supporting previous studies, homology searches revealed that SLK was present in virtually all eukaryotic species, including flies. Northern Blot analysis of different mouse tissues showed three different isoforms of SLK (6, 7, 8 Kb) with the largest one being the most abundant (Sabourin, Seale, Wagner et.al, 2000). All tissues surveyed expressed similar levels of SLK mRNA with lower levels in the liver. The SLK protein has been shown to be expressed in most cell lines and tissues (Al-Zahrani et. al, 2013) and localizes to the cytoplasm.

SLK is a member of the group IV Germinal Center Kinases (GCK-IV). The amino-terminal kinase domain displays sequence similarity to the *Xenopus* polo-like kinase 1 (xPlkk1), MST1 and LOK serine/threonine kinases, playing a role in cell cycle control and apoptosis

(Graves JD, Gotoh Y, Draves KE, et al, 1998). The general structure of SLK consists of 1202 amino acids arranged in three distinct domains: a Ste20 catalytic kinase domain (aa 1-338) near the N-terminal, a central coiled-coil region (aa 339-788) and an AT1-46 homology domain (ATH: aa-789-1202) at the C-terminal end (Figure 1) . A putative SH3 binding site is present at amino acid position 735, suggesting that SLK could directly interact with SH3 domain-containing proteins (Sabourin, Tamai, Seale, et al., 2000).


SLK has been shown to be phosphorylated at serine 189, threonines 183 and 193 (T183 and T193) following auto-activation (Cybulsky et al. 2017). Experiments have shown a 60% reduction in kinase activity with a serine 189 to alanine 189 mutant (S189A) and a T183A/S189A double mutant showed an 80% reduction (Luhovy, Jaber, Papillon et al., 2011). Both sites are never completely phosphorylated, suggesting that they become phosphorylated in a primary and secondary manner. A glutamine 185 mutation (Q185P) that prevents SLK from dimerizing, shows reduced auto-phosphorylation, suggesting that SLK forms a dimer in a trans-orientation prior to auto-phosphorylation (Pike, 2008). Based on deletion studies, it was reported that an important regulatory region lies between amino acids 373 to 592 (Sabourin, Tamai, Seale et al., 2000). The C-terminal ATH domain of SLK also plays a role in the regulation of its activity. SLK-binding proteins include the transcriptional co-activators LMO4, Ldb1, Ldb2, the cytoskeletal protein Actinin and Translocated Promoter Region (TPR) (Jaber A, Hooker E, Guillemette J et.al, 2015, Storbeck CJ, Wagner S, O'Reilly P, et al., 2009). Binding to Ldb1/2 appears to downregulate kinase activity (Storbeck et al., 2009). Supporting this, deletion of the ATH region enhances SLK kinase activity. The various pathways regulating SLK, its regulators and downstream effectors are still being uncovered.

SLK has been shown to play a role in apoptosis, cytoskeletal dynamics and cell migration (Hao W, Takano T, Guillemette J et al., 2006; Wagner et al., 2002; Quizzi JL, Baron K, Al-Zahrani KN, 2013). SLK has distinct functions and likely signals differently depending on the cellular context. In a renal ischemia-reperfusion injury model, SLK reduces the effect of the endoplasmic reticulum stress response and activates the apoptosis signal-regulating kinase-1 (ASK1) (Hao W, Takano T, Guillemette J et al., 2006). ASK1 activation through phosphorylation leads to direct phosphorylation of its downstream target, the p38 mitogen-activated protein kinase (G. Bunkoczi, E. Salah, P. Filippakopoulos et al., 2007). This leads to the release of cytochrome C from its mitochondrial complex that culminates in the activation of caspase 8 and 9. In glomerular epithelial cells, SLK over expression induces apoptosis through the c-Jun N-terminal kinase-1 (JNK1) JNK dependent pathway (Cybulsky AV, Takano T, Guillemette J et. al, 2009). SLK has also been shown to be required for cell cycle progression from G2 to Mitosis (G2/M) and activate the polo-like kinase homolog (PLK1) and cyclin dependent kinase (Ellinger-Ziegelbauer H, Karasuyama H, Yamada E et al., 2000; Reilly P., Wagner S, Franks D., et al. 2005). Both these kinases are important to regulate transit through the cell cycle. In addition to cell death and cell cycle progression, SLK has been demonstrated to regulate cytoskeletal dynamics and cell migration through actin destabilization and focal adhesion dynamics (S.Wagner, C. Storbeck, K. Roovers et al., 2008; Quizzi JL, Baron K, Al-Zahrani KN, 2013).

SLK has been shown to play a critical role in development as the global knock out results in embryonic lethality (Pryce et al., 2017). Consistent with this, an SLK gene trap allele (SLK-LacZ) resulting in an SLK truncation at the ATH domain was found to be embryonic lethal in homozygote mice (Al-Zahrani, K. N., Sekhon, P., Tessier et al, 2014). At embryonic day E12.5, H&E staining showed severe developmental defects in about 40% of the embryos. At E14.5,



almost all of the tissue analysed had anomalies. Mouse embryonic fibroblasts (MEFs) were isolated from SLK-LacZ mice and cultured in vitro. Proliferation assays were performed and it was noted that SLK-LacZ cells grew poorly compared to wild type MEFS, supporting previous data on SLK and cell cycle progression (Ellinger-Ziegelbauer, H., Karasuyama, H., Yamada E., et al., 2000; Wagner, S., Flood T.A., O'Reilly P. et al, 2002).



**Figure 1. Schematic of the murine SLK structure.** The Ste20-like kinase SLK bears a Ste20 signature kinase region (amino acids 1-338) located at the amino terminus (Al-Zahrani et. al, 2013). The kinase domain contains the Ste20 kinase sequence TPYWMAPE. The central coiled coil region extends from amino acids 339-788 and bears a putative SH3-binding domain consensus site (PXXPX) and a consensus caspase 3 cleavage site (DXXD) (Cybulsky et al. 2017, Conway et al. 2017, and Sabourin et al. 2000). The ATH domain is a disorganized region located at the C-terminus and contains a SARA domain. Proteins that are similar in sequence to the kinase region of SLK include LOK and MST1. The AT1-46 and LOK proteins share similarities to the ATH region (Al-Zahrani et. al, 2013). SLK activity is dependent on three main sites (S189, T193, and T183) (Cybulsky et al. 2017, Conway 2017).

## **1.2 SLK and Cell Cycle Control**


The cell cycle is tightly controlled as it is an important process that allows cells the ability to multiply and create new daughter cells (Satyanarayana, Kaldis. 2009). The cell cycle is characterized into different sections which include Mitosis (M phase) and Interphase (Alberts B, Johnson A, Lewis J, et al., 1983, Schafer, K. A., 1998). Interphase consists of S, G1, G2 and G0 sub phases. S phase is when DNA doubles, hence the cell goes from a 2N to a 4N DNA content. In G1, critical proteins are created in order to help the cell move into S phase and create DNA. G2 phase consists of DNA proofreading and repair to get ready for mitosis or M phase (prophase, metaphase, anaphase and telophase), where chromosomes align and divide into two new daughter cells. G0 consists of not actively dividing cells.

Progress in the cell cycle has many proteins that control and coordinate cell cycle events through different checkpoints. Cyclin-dependent kinases (cdks) and cyclin proteins are in charge of various stages in the cell cycle (Devault A, Cavadore JC, Fesquet D et al, 1991; Parker LL, Piwnica-Worms H, 1992; Van den Heuvel S, Harlow E: 1993). Serine/threonine protein kinases, known as cdks, help in mitotic progression. Phosphorylation regulates cdks along with different cyclin levels (Schafer, K.A, 1998) and cyclin interactions that activate cdks. Changes in the levels of varying phase-specific cyclins direct cells through the cell cycle. When one specific cyclin increases, another one is destroyed from a previous phase.

The cell cycle, as described by classic literature, has classified the following: D-type cyclins bind to Cdk4 and Cdk6 during G1, which helps prepare for DNA synthesis (Malumbres, M., Barbacid, M., 2001). These complexes can cause a partial inactivation of the retinoblastoma proteins RBL2, RB and RBL1. E-type cyclins are then expressed and bind to CDK2 (Harbour, J. W., Luo, R. X., Dei Santi, A., et al., 1999). The CDK2-cyclin E complex pushes G1/S transition

(Hochegger, H., Takeda, S., Hunt, T., 2008). When DNA replication is almost over, cyclin A activates CDK2, allowing for transit between S to the start of M phase. Nuclear envelope and cyclin A degradation occurs. CDK1-cyclin B complex forms as a result of the degradation which pushes the cells to pass into mitosis (Malumbres, M., Barbacid, M., 2005).

Interestingly, SLK has been shown to co-localize with the mitotic spindle involved in chromosome alignment and segregation at M phase. Consistent with this, SLK activity is increased during M phase (O'Reilly PG, Wagner S, Franks DJ et al., 2005) and SLK has been shown to be associated with the microtubule network and co-immunoprecipitate with  $\alpha$ -tubulin (Wagner S, Flood TA, O'Reilly P et al., 2002). Expression of kinase-inactive SLK in MEF-3T3 fibroblasts inhibited proliferation and blocked progression through G2. Overexpression of active SLK induced aberrant mitotic entry and spindle formation in MEF-3T3 fibroblasts. Supporting a role for SLK in G2/M, SLK has been shown to phosphorylate and activate Plk1 during the G2 phase of the cell cycle (Ellinger-Ziegelbauer H, Karasuyama H, Yamada E et al, 2000).



**Figure 2 – SLK and cell cycle control.** SLK has been shown to act upstream of PLK1 and Cdc2 in cell cycle progression, during G2/M. Those mechanisms have yet to be clearly elucidated (Al-Zahrani, Khalid N., Kyla D. Baron, and Luc A. Sabourin, 2013).

### **1.3 SLK and Cell Migration**

Cell migration is critical for several processes including morphogenesis, wound repair, maintaining homeostasis and development (Treat et al. 2012). The cytoskeleton is required for integrin-dependent focal adhesion assembly and migration signaling (Bershadsky, 1996).

During cell migration, integrins first attach to the extra-cellular matrix (ECM) (V Bolós, Gasent, J. M., Lopez-Tarruella S. et al., 2010; M. Nagano, D. Hoshino, N. Koshikawa et al. 2012), allowing signaling and scaffold/adaptor proteins to be recruited on the cytosolic side of the cell. These complex structures are referred to as focal adhesions and are made up of several proteins (Paxillin, Talin, Tensin, Zyxin, Vinculin) that provide a strong connection to the actin cytoskeleton (V Bolós, Gasent, J. M., Lopez-Tarruella S. et al., 2010; M. Nagano, D. Hoshino, N. Koshikawa et al. 2012). The assembly of focal adhesions involves the recruitment of focal adhesion kinase (FAK), a major regulator of adhesion signaling. The FAK-integrin complex interacts with the c-Src tyrosine kinase, triggering multiple downstream phosphorylation events critical for the signaling at focal adhesions (V Bolós, Gasent, J. M., Lopez-Tarruella S. et al., 2010; M. Nagano, D. Hoshino, N. Koshikawa et al. 2012). Through its SH2 domains, c-Src binds directly to phospho-tyrosine 397 on FAK. The signaling that ensues induces focal adhesion disassembly. Disassembly is regulated by calpain and microtubules, however the full mechanism has not been fully elucidated. The successive cycles of assembly and disassembly propels the cell forward during migration (V Bolós, Gasent, J. M., Lopez-Tarruella S. et al., 2010; M. Nagano, D. Hoshino, N. Koshikawa et al. 2012).

Scratch wounding in mouse embryonic fibroblasts (MEFs) triggers cell migration and induces SLK activity (Wagner S., Storbeck C., Roovers K. et al, 2008). Interestingly, MEFs that were deficient for FAK showed a lack of SLK upregulation upon scratch wounding when


compared to wildtype FAK MEFs, suggesting that FAK is critical for SLK activation. Different inhibitors (U0126, SB203580) of the MAPK signaling system were used and showed a similar effect on SLK activation, suggesting that the upregulation of SLK activity during migration is dependent on MAPK signaling. It has been shown that SLK is associated with the microtubule network, a component of the cytoskeletal system (Wagner et al., 2002). Interestingly, SLK has also been shown to play a role in the microtubule-dependent focal adhesion turnover after scratch wound-induced migration (Wagner et al., 2008). SLK has been demonstrated to promote focal adhesion turnover by directly phosphorylating Paxillin on serine 250 (Quizi, 2013). It was observed that 293T cells that expressed a Paxillin mutant at the S250 SLK phosphorylation site (S250A), had a two-fold decrease in migration rates, suggesting that SLK is a critical regulator of cell migration. Interestingly, the same Paxillin mutant also delayed the phosphorylation of FAK-Y925, indicating that focal adhesion turnover was impaired.

Factors that have been found to regulate SLK activity and migration rates include the LIM domain binding co-factors Ldb1 and Ldb2 (Storbeck et al., 2009). When Ldb1 levels were reduced, SLK activity was upregulated and migration increased by two-fold while SLK knocked down impaired cell migration. When both Ldb1 and SLK were knocked down, migration was unaffected, suggesting that the increased migration upon Ldb1 knock down is SLK dependent. In disease contexts, SLK activity has been shown to drive breast cancer cell invasion in the presence of Heregulin, an activator of the HER2/Neu oncogene (Roovers K., Wagner S., Storbeck CJ, et al., 2009). As for mouse fibroblasts, the FAK/Src complex was also required for invasion and migration of breast cancer cells and mammary epithelial cells (Roovers K., Wagner S., Storbeck CJ, et al., 2009). Recently, LMO4 was found to interact directly with the ATH domain of SLK (Baron et al., 2015). It has been shown that the activation and recruitment of



SLK at the leading edge of migrating cells requires the LIM-only protein 4 (LMO4) and Src family kinase activity (Baron et al., 2015). LMO4-deficient cells failed to recruit SLK at the leading edge and to induce SLK kinase activity upon scratch wounding. SLK also co-localizes with Rac1, a regulator of actin stress fiber dynamics, at the leading edge of migrating cells (Wagner et al., 2002). Supporting a role for SLK in focal adhesion breakdown, overexpression of SLK induces actin stress-fiber disassembly, focal adhesion disassembly and apoptosis in C2C12 myoblasts (Sabourin et al., 2000). The v-Src oncogene has been shown to inhibit SLK activity indirectly through CK2 activation. SLK has been shown to be directly phosphorylated by Casein Kinase II (CK2) downstream of v-Src, resulting in the downregulation of SLK kinase activity (Chaar et al., 2006). Supporting this, SLK catalytic activity could be restored following CK2 inhibition in v-Src transformed cells.

In adult mice, SLK-null skeletal muscles show Paxillin mis-localization while wildtype muscles have a normal Paxillin distribution at costameres. FAK also displayed an altered localization and patchy distribution throughout the myofibers. This impaired localization might be responsible for the observed defects in the myotendinous junctions and myofibers stability.



**Figure 3. Mechanisms of SLK recruitment and activation during cell migration.**

Downstream of growth factor receptor activation or direct integrin engagement with the ECM, the FAK/src complex is stimulated (Al Zahrani et. al, 2013), triggering signaling events that lead to SLK activation. SLK is recruited to the leading edge where it can phosphorylate Paxillin to induce focal adhesion destabilization. Focal adhesion turnover propels the cell forward in the direction of migration/invasion. The Ldb1/2 proteins can play a role in modulating SLK activity depending on the context (Storbeck, 2009).

## **1.4 SLK and Apoptosis**

The word apoptosis was coined by Kerr and colleagues in 1972 to illustrate the physically unique appearance of a cell's "loss of life" (Kerr et al, 1972; Paweletz, 2001; Kerr, 2002; Susan E., 2007). Apoptosis is defined as programmed cell death (Susan E., 2007). In other words, cells lose their viability at distinct or regulated stops during certain cellular processes. Some features of apoptotic cells are that they have DNA breakdown, cleavage of proteins and cross-linking of proteins. Apoptosis was first studied in the nematode *Caenorhabditis elegans* (Horvitz, 1999; Susan E., 2007). Out of the 1090 somatic cells of the nematode, 131 underwent apoptosis between different stages highlighting the importance of this process for the control of cell number (Horvitz, 1999; Susan E., 2007). Other processes where apoptosis has been shown to occur include: aging, development and homeostatic cell population maintenance. For example, aging females have a higher rate of apoptosis for their oocytes than younger women possibly suggesting why older women have lower fertility (Wu J, Zhang I, Wang X, 2000; Muradian K, Schachtschabel DO., 2001). When cells have been damaged by toxins and/or pathogens or are under attack due to an immune response, apoptosis can occur to protect the organism (Norbury and Hickson, 2001; Susan E., 2007). Different stimuli cause apoptotic death through different signaling pathways. Current literature has divided apoptotic pathways into two categories: intrinsic (mitochondrial pathway) and extrinsic (death receptor pathway) (Igney FH, Krammer PH, 2002; Susan E., 2007). There is also evidence that connects both pathways to each other and studies that suggest the existence of a third system known as the perforin/granzyme pathway. These systems eventually lead to a final stage known as the execution pathway.

### ***The Extrinsic Signaling Pathway***

This pathway is initiated by the activation of a transmembrane receptor-mediated interaction with a death signal or ligand (Hsu et al., 1995; Grimm et al., 1996; Wajant, 2002; Susan E., 2007). Death receptors, from the tumor necrosis factor (TNF) family, play an important role in this process. There are two critical death receptor pathways: the TNF- $\alpha$ /TNFR1 and the FasL/FasR. Ligand-mediated receptor clustering triggers the recruitment of adaptor proteins (FADD or TRADD) that interact with procaspase-8 (Hsu et al., 1995; Grimm et al., 1996; Wajant, 2002; Susan E., 2007). This death-inducing complex (DISC) activates Procaspase-8 through auto-catalysis, leading to the execution phase of apoptosis.

### ***The Intrinsic Signaling Pathway***

There are several stimuli that can cause apoptosis either through negative signals (lack of key components for cell survival) or positive signals (infections, radiation etc.). All of those stimuli disrupt mitochondrial function culminating in cell death (Saelens et al., 2004; Susan E., 2007). Two groups of pro-apoptotic proteins are key for intrinsic apoptosis. The first group is made up of the serine protease HtrA2/Omi, Cytochrome C and Smac/DIABLO (Cai et al., 1998; Du et al., 2000; Loo et al., 2002; Garrido et al., 2006; Susan E., 2007). The second is made up of endonuclease G, CAD and AIF (Jozsa N, Susin SA, Daugas E et al., 2001; Susan E., 2007). These factors all have pro-apoptotic activity in the intrinsic cascade.

Caspases are the ultimate effectors of the apoptotic response. They can be divided into initiator caspases (caspases 2, 8, 9, and 10), executioner (caspases 3, 6, and 7) and inflammatory (caspases 1, 4, and 5) (Cohen, 1997; Rai et al., 2005; Susan E., 2007). Other caspases include 11, 12, 13 and 14 with their own distinct roles. Caspase 11 helps cytokines mature during septic shock and regulates apoptosis (Kang et al., 2002; Susan E., 2007). Caspase 12 controls the cytotoxic effects of amyloid- $\beta$  and apoptosis specific to the endoplasmic reticulum (Nakagawa et

al., 2000; Susan E., 2007). Caspase 13 was initially thought to be solely in humans, but later found to be in cattle (Koenig et al., 2001; Susan E., 2007). Caspase 14 is expressed in low amounts within adult tissues but at very high levels within embryonic tissues (Hu et al., 1998; Susan E., 2007). It has been shown to play a role in epidermal barrier formation (Denecker G., E. Hoste, B. Gilbert et al., 2007; Denecker G., Ovaere P., Vandenabeele P. et al, 2008). Most cells have inactive caspases. Once those inactive initiator caspases are activated, they cleave the pro-caspase forms to activate executioner caspases, resulting in a protease cascade (D. McIlwain, T. Berger, T. Mak, 2013; Hengartner, 2000). This chain of events, known as the proteolytic cascade, accelerates the apoptotic signaling pathway and ultimately cell death. Both the intrinsic and extrinsic pathways eventually culminate in the activation of executioner caspases which then trigger several downstream processes including protein cross-linking, apoptotic body formation, degradation of nuclear and cytoskeletal proteins and DNA fragmentation (Igney FH, Krammer PH, 2002; Susan E., 2007).

### ***Execution Pathway***

Executioner caspases activate cytoplasmic endonucleases and proteases to breakdown nuclear material and proteins. They cleave multiple substrates such as poly (ADP-ribose) polymerase (PARP) and cytokeratins which causes the cell to change biochemically and morphologically. PARP helps in transcription, DNA repair and other processes (Morales J., Longshan L., Farjana F. et al., 2016). Caspase 3 cleaves ICAD (CAD inhibitor) to release the endonuclease CAD, causing degradation of chromosomal DNA (Sakahira H, Enari M, Nagata S, 1998; Susan E., 2007). Caspase-3 also cleaves the actin-binding protein Gelsolin and the cleaved portions negatively affects cell division, intracellular transport, the cytoskeleton and multiple signaling pathways (Kothakota S, Azuma T, Reinhard C, et al., 1997; Susan E., 2007). The

apoptotic cells also externalize phosphatidylserine residues on the cell surface (Susan E., 2007), allowing for non-inflammatory phagocytic recognition (Fadok VA, de Cathelineau A, Daleke DL, et al., 2001).

Interestingly, SLK was also shown to induce apoptosis in C2C12 myoblasts when overexpressed, by activating the c-Jun-N-terminal kinase 1 (JNK1)-dependent pathway (Sabourin LA, Rudnicki MA, 1999; Yan Y, Tulasne D, Browaeys E, 2007; Al-Zahrani, KN., Baron KD, and Sabourin LA, 2013). In another study, SLK overexpression lead to membrane blebbing, actin redistribution to the periphery of the cell, actin stress fiber dissolution and loss of substrate adhesion (Sabourin LA, Tamai K, Seale P, 2000; Al-Zahrani, KN., Baron KD, and Sabourin LA, 2013). Expression of active SLK caused rapid apoptosis while expression of the ATH domain caused a delay in apoptosis. A number of apoptotic triggers were shown to induce caspase 3-mediated cleavage of SLK, releasing the active kinase region, thereby accelerating apoptosis. In the context of renal ischemia-reperfusion injury, SLK expression increased the endoplasmic reticulum (ER) stress response through ASK-1 and p38. In glomerular epithelial cells, SLK overexpression induced p53 activity through the JNK pathway (Cybulsky AV, Takano T, Guillemette J et al., 2009; Al-Zahrani, KN., Baron KD, and Sabourin LA, 2013). The same effect was seen in a transgenic mouse line that overexpressed SLK in kidney glomerular podocytes (Cybulsky AV, Takano T, Papillon J et al., 2010; Al-Zahrani, KN., Baron KD, and Sabourin LA, 2013). This led to a loss of the podocytes, coupled with an elevation of p38 activity. In glomerular epithelial cells, SLK overexpression also induces the HSF1-HSP70 pathway (Cybulsky AV, Guillemette J, Papillon J. et al, 2016). HSF1 is involved in the transcription of various other heatshock proteins that help control protein folding, such as HSP70.

## **1.5 Rationale and Hypothesis**

Numerous studies have shown that SLK plays a critical role in cell cycle transit and cell migration. It has also been demonstrated to be a substrate for Caspase 3, suggesting that it may have an active function in cell death (Ellinger-Ziegelbauer H, Karasuyama H, Yamada E et al., 2000; Reilly P., Wagner S, Franks D., et al. 2005; Hao W, Takano T, Guillemette J et al., 2006; Wagner et al., 2002; S. Wagner, C. Storbeck, K. Roovers et al., 2008; Quizi JL, Baron K, Al-Zahrani KN, 2013). The recent generation of a conditional SLK-floxed allele has allowed us to derive SLK-null fibroblasts to test the effect of an actual genetic deletion of SLK on those processes. Our hypothesis was that the deletion of SLK would markedly delay cell growth, migration and apoptosis. We tested this using the following approaches:

## **1.6 Objectives**

1. Test the effect of SLK deletion on the proliferation of embryonic fibroblasts using cell counts, Flow Cytometry and Western blotting for cell cycle markers.
2. Test the effect of SLK deletion on the migration potential of fibroblasts using Boyden Chamber Migration Assays, scratch wounding and Nocodazole wash outs.
3. Test the effect of SLK ablation on cell death and apoptosis signaling using various triggers.



## **2. Materials and Methods**

### **2.1. Cell Culture**

Mouse Embryonic Fibroblasts (MEFs) were cultured in DMEM 1X (Dulbecco's Modified Eagle's Medium), 2mM L-glutamine (Invitrogen), with 200 U mL<sup>-1</sup> penicillin/streptomycin (Invitrogen), and 10% fetal bovine serum (FBS; Invitrogen). All experiments were performed in complete medium as described above. Cells were grown in an incubator that was humidified and set at a temperature of 37°C with 5% CO<sub>2</sub>. For Nocodazole (450 µM) arrest experiments, MEFs cells were always arrested for 24 hours prior to re-feeding with full media.

### **2.2 Western Blots and Protein Harvesting**

Proteins were extracted with cell scraping from a 10 cm plate. 0.5 mL 1xPBS was the final volume, prior to washing with 1 mL of 1X PBS, which was collected to be spun in a centrifuge at 8000 rpm for 3 minutes (1xPBS was made from a 10x solution which consisted of: 2.1g Na<sub>2</sub>HPO<sub>4</sub>, 500mL H<sub>2</sub>O, 45g NaCl, 0.72g KH<sub>2</sub>PO<sub>4</sub>) (Conway, J., Sabourin, L., 2016). Afterwards, the pellets were lysed with RIPA (1mg/mL leupeptin, 1M DTT, 150 mM NaCl, , 1M β- glycerophosphate, 0.05% SDS, 1M NaF, 1% Igepal CA-630, 0.1M PMSF, 1% Triton X-100, 1M Tris, 50 mM Tris-HCl, pH 7.5, 12 mM Na-Deoxycholate buffer, 1mg/mL pepstatin, 2 mM EDTA, pH 8.0, 0.2M NaVO<sub>3</sub>, 100µM benzamide, , 1mg/mL aprotinin)(Conway, J., Sabourin, L., 2016). Protein lysates were spun at 13500 rpm for 10 minutes to isolate the protein. Bradford Lowry Reagent was used to determine the protein concentration (Bio-Rad, Mississauga, Ontario, Canada) (Conway, J., Sabourin, L., 2016). For western blotting, 10-20 µg of total protein was electrophoresed on an 8, 10 or 12% polyacrylamide gel (depending on the experiment) and transferred onto a PVDF (polyvinylidene difluoride) membrane (Thermo Fisher Scientific, USA)

(Conway, J., Sabourin, L., 2016). BSA (5%) was used to block the membranes (Sigma-Aldrich, Oakville, Ontario, Canada). Membranes were mixed with primary antibodies in 1xTBST (150 mM NaCl, 0.05% Tween 20, 50 mM Tris, pH 7.4)(Conway, J., & Sabourin, L., 2016) for one hour at room temperature (or overnight). The membrane underwent 3 1xTBST washes, of 5 minutes. The primary antibody was then probed with a secondary antibody (Horseradish peroxidase-coupled from Bio-Rad, USA) and visualized with Western Lightning Plus chemiluminescence (Perkin-Elmer, USA). The following primary antibodies were used: anti-SLK (custom antibody, Japan, (Wagner, et al., 2008)), anti- $\alpha$ -tubulin (Sigma-Aldrich, Oakville, Ontario, Canada), Paxillin, FAK, phospho-FAK-Y397 (BD transduction laboratories, Mississauga, Ontario, Canada), Myc (Sigma- Aldrich; 9E10 mouse ascites), Beta-Actin (Sigma, A5316), PARP (Cell Signalling Technology, 9542), JNK1 (Cell Signalling, 9252), p-JNK (T183/Y185)(Cell Signalling, 9251), p38 (Cell Signalling, 9211), p-p38 (T180, Y182) (Cell Signalling 9211), ASK1 (Cell Signalling, 3762), p-ASK(966)(Cell Signalling Technologies), Caspase 3 (Cell Signalling, 9662), Cyclin D1 (Santa Cruz, sc-20044), Cyclin A (Santa Cruz, sc-271682).

### **2.3 Transfections**

For transfections, MEFs were seeded at 50000 cells on a 6 cm plate and transfected the next day. The cells were transfected with Polyethylenimine (PEI - linear, 25,000 MW) in serum-free media, and changed for a 10 cm plate according to details specified by the manufacturer. The transfection mix was then added to the adherent cells and topped up with 10% FBS DMEM after 3 hours. The cells were harvested 48 hours following transfection.

### **2.4 Proliferation Assay**

Cells were seeded in cell culture plates at an initial density of 50,000 cells in 6 cm plates in biological triplicates and counted every day for up to 8 days. Cells were removed through trypsinization and collected using a centrifuge at a speed of 1200 rpm for 3 minutes. The cells were then washed in PBS and collected in 2 mL of media. Technical triplicates, three individual counts from the same sample, were also taken using the Beckman Vi-Cell cell counter.

## **2.5 Flow Cytometry**

Cells were seeded on 10 cm plates at around 70% confluency. On the following day, they were exposed to 450  $\mu$ M Nocodazole for 24 hours. Cells were then released from arrest in complete media and collected at the indicated time points (0, 3, 6, 18, 20 hours). The cells were washed, trypsinized and spun at 1200 rpm for 5 minutes. They were then fixed in cold 70% ethanol and stained with Propidium Iodide Buffer (100  $\mu$ g/mL RNaseA, 0.2% Triton-X, 25  $\mu$ g/mL propidium Iodide, 0.5M EDTA, pH 8.0). The stained cells were then gated and counted using flow cytometry (Beckman Coulter MoFlo XDP).

## **2.6 Boyden Chamber Migration Assay**

Boyden chambers were coated the night before with fibronectin (1% of total volume used, dissolved in PBS) and incubated at 4°C. Cells were serum-starved 24h before the experiment. 50,000 cells were placed in the top portion of the Boyden chamber in a volume of 400  $\mu$ L. The bottom chamber was also placed in 400  $\mu$ l of media. SLK wildtype and SLK (-/-) cells were seeded into Boyden chambers in triplicate and allowed to migrate for 6 hours. Migration time and serum concentration were optimized in separate experiments and migration assays were performed for 6 hours at 1% FBS (bottom and top chamber), in DMEM to measure haptotaxis. The cells that remained on the bottom part of the chamber were fixed with 10%

buffered formalin phosphate and finally stained with 0.5% crystal violet (dissolved in 25% methanol) for quantification after imaging.

## **2.7 Alamar Blue Apoptosis Assay**

SLK (fl/fl) and SLK (-/-) cells were seeded at 70-80% density (5000 cells) in a 96 well plate in quadruplicates for each time point. The following day, the cells were exposed to specific apoptotic triggers (1  $\mu$ M Staurosporine/ 150  $\mu$ M Etoposide/ 4  $\mu$ M Chelerythrine; Cell Signaling and Sigma) for the indicated time (0, 3, 6, 12, and 24). Staurosporine is a protein kinase C inhibitor and also inhibits other kinases at higher concentrations (Ruegg, U. T. and Burgess, G. M., 1989). Etoposide is used for chemotherapy and it causes DNA damage by stopping Topoisomerase II (Jamil S, Lam I, Majd M et al., 2015). Chelerythrine acts as a strong inhibitor towards protein kinase C, causes DNA fragmentation and cell death (Barg, J. et al, 1992). Following treatment, the cells were mixed with Alamar blue (10x) solution and live/dead cells were quantitated, 4 hours after to allow the reagent to change color, using a Fluorescence Multiskan reader at 570 nm and 604 nm.

## **2.8 Immunofluorescence**

For the Scratch Wound Assay, the cells were plated on glass coverslips in 6 well plates and grown to confluency. The monolayers were then scratched with a pipet tip and allowed to migrate into the wound for t=0 and 60 minutes. For the Nocodazole Arrest Assay, cells were plated at 50,000 cells on a 6 well plate. Subconfluent monolayers were re-fed with full media the following day and treated with 450  $\mu$ M of Nocodazole for 24 hours, then fixed at t= 0 and 45 minutes with 4% PFA following nocodazole wash-out. From this point on, the procedure

remains the same for both assays. Media was removed and the cells were washed with 1X PBS. Cells were then fixed with cold 4% PFA (Paraformaldehyde) for 10 minutes. They were then washed with 1X PBS three times and permeabilized with 0.1% Triton (mixed with PBS) for 10 minutes. They were then washed again with PBS three times. The coverslips were blocked with 5% goat serum, diluted in PBS, (Original stock 45-75 mg/mL) for 1 hour. Primary antibody diluted in 5% goat serum was then added at room temperature. Fluorescent secondary antibodies were then added to bind to the primary antibodies with 5% goat serum. ProLong Gold antifade reagent with DAPI (4, 6-diamidino-2-phenylindole) was added to the coverslips and then sealed with nail polish. Images were captured using a Zeiss AxioCam Fluorescence Microscope.

## **2.9 Immunoprecipitation**

Different Melanoma cell lines were seeded at an equal density on 10 cm cell culture plates. Cells were harvested and collected into an Eppendorf tube and lysed in RIPA lysis buffer. At least 300 µg of total protein were used in immunoprecipitations. 20 µL of protein A-Sepharose 4 Fast Flow beads were added to the tubes along with 1 µL of SLK primary antibody. The sample were incubated for 2 hours at 4 ° C and washed three times with NETN (200 mM NaCl, 20 mM Tris-HCl, pH 8.0, 0.5% NP-40, 1 mM EDTA, pH 8.0) (Al-Zahrani, 2018) buffer to remove non-specific binding. SDS sample buffer was then added to the samples, heated at 100 ° C for 5 minutes and fractionated by SDS-PAGE for western analysis.

## **2.10 In-vitro binding assay**

Binding assays were performed to test the binding between the SLK and RASSF1A. For the binding assays, recombinant proteins were prepared using GST fusion constructs. GST and GST-fusion plasmids were transformed into DH5α E. coli and clones were isolated. Bacterial


clones were inoculated the night before the experiment. One tenth of the culture was then transferred into a new flask and grown for an hour at 37 ° C. Protein expression was induced using 1 mM Isopropyl  $\beta$ -D-1-thiogalactopyranoside (IPTG) for 2 hours at 37°C. The samples were then spun down and the cell pellets were lysed using 500  $\mu$ L of RIPA lysis buffer. To prevent protein degradation, the tubes were constantly kept on ice. The cells were subjected to sonication and vortexed every 5 minutes for 15 minutes. The samples were cleared for 30 minutes at 13500 rpm at 4 ° C and the supernatant was transferred into fresh chilled tubes and 20  $\mu$ L of GST sepharose beads were added. The tube was rotated for 2h to isolate the GST-fusions. In vitro translation of HA-RASSF1A or Myc-SLK was performed using the TNT reticulocyte lysate system and purified plasmid DNA in the presence of  $^{35}$ S-Methionine. The isolated GST and GST-fusion samples were washed with NETN to remove non-specific binding. The in-vitro translated products were then incubated with the GST-fusions for 45 minutes at room temperature. The samples were then washed with NETN, denatured and loaded onto SDS gels. The gels were stained with coomassie blue, washed with water and enlightening agent to increase the radioactive signal of  $^{35}$ S. The gel was dried down and exposed to X-ray film at - 80°C.

### **3. Results**


#### **3.1 Generation of SLK-deficient Fibroblasts**

Prior to the start of this project, Dr. Khalid Al-Zahrani from the Sabourin lab had generated SLK-deficient mouse embryonic fibroblasts (MEFs) from a conditional SLK floxed allele (**Figure 4A**). Briefly, 14.5 day old embryos were obtained from timed matings by caesarean section, decapitated and dissociated by trypsinization. The cell line was established following a 30 day period in culture. To delete SLK, cultures were exposed to AdCre virus or an AdGFP control (**Figure 4B**). As shown in **Figure 4C**, AdCre-infected SLK floxed MEFs are devoid of SLK proteins, suggesting complete inactivation of the SLK gene.


**A.**



**B.**



**C.**






**Figure 4. Generation of SLK-deficient Fibroblasts.** (A) Diagram depicting the floxed SLK allele. Exons 3-6 were flanked by LoxP sites and a Neo cassette flanked by FRT sites was inserted in intro 2. Infection with AdCre deletes exons 3-6 (recombined locus) (Pryce, B. R., Al-Zahrani, K. N., Dufresne, S et al, 2017). (B) Validation of the genetic deletion of SLK illustrated by shift in the  $\Delta$ 3-6 PCR products encompassing the deleted region (done by John Abou-Hamad). (C) Western blot analysis of fibroblast extracts showing loss of SLK protein in Cre-infected cells.


### **3.2 SLK deletion in MEFs does not impair proliferation in vitro**

Previous studies from our lab have shown that SLK kinase activity is induced during G2/M and that the expression of a kinase dead SLK in MEF-3T3 cells induces a G2/M cell cycle arrest (PG. O'Reilly, 2005). Supporting this, expression of active SLK induces ectopic spindle formation and mitotic catastrophe. Similarly, cells expressing a mutant SLK-LacZ gene trap fusion protein showed reduced proliferation (Al-Zahrani KN, Sekhon P, Tessier DR et al., 2014). Together these data suggest that SLK is critical for progression through the cell cycle. To assess the effect of an SLK genetic deletion on proliferation, we tested the growth potential of SLK-deficient MEFs. MEFs cells were plated at equal densities and growth was monitored over time. Surprisingly, the deletion of SLK had no effect on the proliferation of the MEFs in vitro in complete medium (**Figure 5**). This suggests that SLK is not required for the growth of MEFs in vitro or that compensatory pathways have been activated. To test the effect of SLK deletion on cell cycle distribution, Nocodazole-arrested cultures were released in complete medium and subjected to flow cytometry following Propidium iodide staining. As for the cell counts, no differences were observed in the cell content of the different cell cycle phases (**Figure 6A**). Supporting this, the expression pattern for cyclin A (G2/M phase) and cyclin E (S phase) were similar between the two cell lines, suggesting that SLK deletion does not affect cell cycle transit (**Figure 6B**). To further elucidate if there is a potential difference in growth, the time period of all the proliferation experiments could have been increased to 64 hours because 32 hours might have not been a long enough time frame to observe any changes.




**Figure 5. SLK deletion in MEFs does not impair proliferation *in vitro*.** Cells were plated at an equal density, in 6 cm plates, and counted daily for 7 days in biological and technical triplicates using the Beckman Vi-Cell cell counter (n=3). No difference in growth between SLK(fl/fl) and SLK(-/-) MEFs were observed.

A.



B.




**Figure 6. SLK deletion does not impair cell cycle progression.** (A) Cells were arrested in 450  $\mu$ M Nocodazole, refed in full media and fixed at specific time points for staining with Propidium Iodide and flow cytometry analysis. No difference in the percentage of cells in G2/M compartment was observed between SLK(fl/fl) and SLK(-/-) MEFs (n=3). (B) Cells were arrested in 450  $\mu$ M Nocodazole and analysed by Western Blot for cyclin A and E. No change in cyclin levels were observed between SLK(fl/fl) and SLK(-/-) MEFs over a 32 hour time course.


### **3.3 SLK Deletion does not impair cell Migration**

It has been shown that SLK is associated with the microtubule network (Wagner et al., 2002). In addition, SLK was shown to phosphorylate the signaling adapter Paxillin, critical for cell motility (Quizil, 2013). When a Paxillin mutant (S250A) at an SLK phosphorylation site was expressed in 293T, migration rates decreased two-fold. Similarly, when SLK was knocked down in cells that were activated by heregulin, migration was inhibited by 75% (K Roovers, S Wagner, CJ Storbeck et al., 2009), strongly supporting a role for SLK in cell migration. Therefore, motility was assessed in MEFs using a Boyden Chamber migration assay. Boyden chambers were coated with fibronectin the day before the experiment. Equal amounts of both wildtype and SLK-null cells were seeded in biological and technical triplicates and allowed to migrate to the fibronectin-coated side. Surprisingly, there were no detectable differences in motility rates between the two cells lines (**Figure 7A**). Similarly, no differences were observed in the relative levels of migration signaling components such as Paxillin and FAK by Western blot (**Figure 7B**). These results suggest that SLK-deficient MEFs might have activated compensatory pathways to bypass the requirements for SLK during cell migration. There could also be compensation by a splice variant of SLK, as potentially predicted by past experiments, and they may not be detected by the regular SLK antibody due to possible post-translational modifications ((Sabourin LA and Rudnicki MA, 1999) (Sierra Delarosa, 2009).

A.



B.






**Figure 7. SLK deletion does not impair cell migration (A)** An equal density of cells were placed on top of the Boyden chambers, left to migrate for 6 hours, fixed with 10% buffered formalin phosphate and finally stained with 0.5% crystal violet (dissolved in 25% methanol) for quantification after imaging. No difference in migration rates were seen between SLK (fl/fl) and SLK (-/-) MEFs. **(B)** Western blot analysis showing that the levels of critical migration signaling proteins are unaffected (n=3).


### **3.4 SLK deletion enhances Nocodazole washout-induced focal adhesion turnover**

Microtubule polymerization and contact with focal adhesions have been shown to induce their destabilization (Kaverina et al., 1999). Similarly, Nocodazole treatment induces focal adhesion stabilization and accumulation of pFAK-Y397 (Kaverina et al., 1998), whereas Nocodazole release induces a loss of pFAK-Y397, indicative of focal adhesion turnover. We have previously shown that SLK is activated downstream of the FAK/Src complex, required for focal adhesion turnover and cell migration (S. Wagner, C. Storbeck, K. Roovers et al., 2008). To assess the effect of SLK deletion on focal adhesion turnover, we monitored the levels of pFAK-Y397 following Nocodazole treatment. Although no difference in motility was observed, the loss of pFAK-Y397 was more rapid in SLK-null MEFs, suggesting that microtubule-dependent focal adhesion turnover is faster (**Figure 8A**). An immunofluorescence experiment was done to validate this finding, however no difference was observed through immunofluorescence (**Figure 8B & 9**). This is in stark contrast to what has been observed in SLK knockdown studies. Interestingly, scratch wounding of SLK-null MEFs still results in the recruitment of FAK and Paxillin at the leading edge of migrating cells, suggesting that SLK is not required for this process (**Figure 10**).

A.




B.




**Figure 8. SLK deletion enhances Nocodazole washout-induced focal adhesion turnover (A)** Sub-confluent monolayers were arrested with 450  $\mu$ M Nocodazole, refed with full media and finally harvested for western blot analysis at specific time points. A more rapid loss of pFAK-Y397 was observed in SLK (-/-) MEFs, suggesting altered kinetics. **(B)** Focal adhesion size was assessed by fluorescence microscopy following Nocodazole washout. No change in focal adhesion size was observed. Focal adhesions that did not fit the bin sizes were excluded from the graph due to them being false positives outside the average focal adhesion size. Quantification was done through ImageJ and is thoroughly explained by the following paper (Horzum U., Ozdil B., Pesen-Okvur D., 2014) (n=3).

A.




B.




**Figure 9. SLK deletion does not alter focal adhesion size (A)** In Figure 8, cells were arrested with 450  $\mu$ M Nocodazole, refed with full media and fixed with 4% PFA for total FAK immunofluorescence analysis. The size of the FAK-positive adhesions was quantitated. **(B)** The boxed regions in (A) are shown at higher magnification. Adhesions are indicated by the arrowheads (n=3).

A.



B.



**Figure 10 – SLK is not required for Paxillin localization at the leading edge.** (A) Confluent monolayers were subjected to Scratch Wound Assays and Paxillin localization was assessed by immunofluorescence. Paxillin was still recruited to the leading edge in SLK-deficient cells. Arrowheads show Paxillin at the leading edge of cells migrating into the wound (n=3). (B) Close up immunofluorescent images of Paxillin (SLK (-/-) on the left, SLK (fl/fl) on the right).




### **3.5 SLK is not required for programmed cell death**


Previously SLK overexpression was shown to induce apoptosis and to activate JNK in various cell lines and podocytes (Sabourin LA, Rudnicki MA, 1999; Yan Y, Tulasne D, Browaeys E, 2007; Al-Zahrani, KN., Baron KD, and Sabourin LA, 2013; Cybulsky AV, Takano T, Guillemette J et. al, 2009). Furthermore, apoptotic triggers induced the caspase 3-mediated cleavage of SLK into its active kinase domain and the actin-regulating ATH region (Sabourin LA and Rudnicki MA, 1999). To test the effect of SLK deletion on cell death, wildtype and SLK-null MEFS were exposed to various apoptotic triggers. Both cell lines were treated with etoposide, Staurosporine or Chelerythrine and monitored for cell viability by Alamar blue over 24 hours. Surprisingly, SLK deletion had no effect of cell viability and did not delay cell death upon exposure to the apoptotic triggers (**Figure 11**). As previously reported, SLK was observed to breakdown during cell death (see **Figure 12-14**; Sabourin L.A., Tamai K, Seale P., et al., 2000). To further investigate the role of SLK in cell death signaling, both wildtype and knockout cells were treated with Staurosporine for a period of 6 hours and the activation or levels of apoptotic markers were assessed. Western Blot analysis showed no differences in PARP cleavage and caspase 3 activation between the two cell lines (**Figure 12A**). Other drugs also displayed the same phenotype (**Figure 12B, C**). Similarly, no changes were observed in the activation status of JNK and p38 (**Figure 13**). Interestingly, higher levels of total and inactive ASK-1 (pS966) were observed in SLK-deficient cells, suggesting that the loss of SLK delays ASK-1 activation and degradation during cell death (**Figure 13**). However, this had no effect on p38 activity, an ASK-1 target (Watanabe T., Sekine S., Naguro I., et al, 2015). One possibility is that ASK-1 dephosphorylation at serine 966 affects its stability and might be SLK-dependent. Due to the

availability of an SLK-deficient Neu-expressing breast cancer line (Al Zahrani K., Sabourin L., 2018), we tested the role of SLK in apoptosis in the context of transformation. Wildtype and SLK-null NDL cell lines (Neu Deleted Line; Al Zahrani K., Sabourin L., 2018) were treated with Staurosporine for 48 hours and assessed for apoptotic markers. As for MEFs, SLK was also shown to breakdown in the NDLs. Along with PARP cleavage and p38 activation, this was markedly delayed (**Figure 14**), consistent with an apoptosis-resistant transformed phenotype. Overall, our data show that SLK deletion does not significantly affect cell death in normal or transformed cells. In conclusion, the results show that SLK is not required for proliferation, migration or apoptosis in MEFs that were genetically deleted for SLK. However, pFAK(Y397) levels differ post Nocodazole arrest which suggests a possible change in focal adhesion turnover.


A.




B.




C.



D.



**Figure 11. SLK is not required for programmed cell death.** Cultures of SLK-null and wildtype cells were exposed to 1  $\mu$ M Staurosporine (A, B), 150  $\mu$ M Etoposide (C) or 4  $\mu$ M Chelerythrine (D) and cell viability was assessed using Alamar blue (5x). No difference in viability or Apoptosis rates were observed throughout the time courses between the two cell lines.




**Figure 12. SLK deletion does not affect PARP breakdown or Caspase 3 activation. (A)**

MEFs were treated with 1  $\mu$ M Staurosporine for 6 hours and assessed for SLK, PARP and

Paxillin levels by Western blot analysis. **(B)** Western analysis for SLK, PARP and Caspase 3


following 150  $\mu$ M Etoposide treatment **(C)** Western analysis for SLK, PARP and Caspase 3

following 4  $\mu$ M Chelerythrine treatment. All treatments showed SLK and PARP breakdown as well as caspase 3 activation (cleaved caspase).



**Figure 13. Apoptotic signaling in SLK-null cells.** Staurosporine (1  $\mu$ M) was used to induce apoptosis in MEFs over a time course of 6 hours. Protein extracts were analysed by Western blot for the activation status of various kinases implicated in cell death and stress response [pp38 (phospho-p38, Thr180 and Tyr182), ppJNK (phosphor-JNK, Thr183 Tyr185), pASK1 (phospho-ASK1 Ser966)]. Caspase 3 shows cleaved and active caspase 3.





**Figure 14. Apoptotic signaling in Neu-transformed SLK-null cells.** Staurosporine (1  $\mu$ M) was used to induce apoptosis in Neu-positive breast cancer cells (NDL; established by Dr. Khalid Al-Zahrani) over 48 hours. Protein extracts were analysed by Western blot for the activation status of various kinases implicated in cell death and stress response [pp38 (phospho-p38, Thr180 and Tyr182), ppJNK (phospho-JNK, Thr183 and Tyr185), pASK1 (phospho-ASK1 Ser966)].

## **4. Discussion**

To assess the role of SLK in various biological processes we have analyzed the growth potential, motility and apoptotic response of SLK-deficient MEFs. In contrast to previous observations using acute knock down, our data show that the genetic deletion of SLK in MEFs does not affect proliferation or susceptibility to apoptotic triggers. Although motility was unaffected, differences in focal adhesion turnover were observed, suggesting that compensatory mechanisms have been activated in SLK-null cells.

### **4.1 SLK is not required for the growth of Mouse Embryonic Fibroblasts in vitro**

Our lab has previously shown that SLK co-localizes with the mitotic spindle during M phase and is required for progression through G2/M (O'Reilly PG, Wagner S, Franks DJ et al., 2005). SLK was also shown to phosphorylate and activate PLK1 during mitosis (Ellinger-Ziegelbauer H, Karasuyama H, Yamada E et al, 2000). Expression of a kinase dead SLK results in a G2/M arrest in fibroblasts and sustained expression of cyclin A, suggesting that SLK is required for cell cycle progression. Supporting this, MEFs expressing an SLK gene-trap (SLK truncation), which involved removing the ATH domain (known for regulating SLK kinase activity) (Sabourin, Tamai, Seale et al., 2000), displayed reduced growth potential when compared to wildtype MEFs (Al-Zahrani, K. N., Sekhon, P., Tessier et al, 2014). Using viable cell counts, we did not observe any differences in the growth rate of SLK-deficient cells (**Figure 5**). Similarly, flow cytometry and Nocodazole release studies did not show any delay in the G2/M transition for the SLK-null cells (**Figure 6A**). Supporting this, western blotting showed similar levels of cyclin A expression following release (**Figure 6B**). Together, our data suggests that SLK is not required for proliferation in MEFs in vitro. For future experiments, it would be better to increase the time-course to see whether the cells require a longer period of time to exit

Nocodazole arrest. This is in stark contrast to previous data using kinase inactive SLK (O'Reilly PG, Wagner S, Franks DJ et al., 2005). One particular study could potentially explain these differences (Hall EA, Keighren M, Ford MJ et al. 2013). It focuses on a gene known as 5-azacytidine induced gene 1 (Azi1)/Cep131 that plays a role in ciliogenesis. Azi1/Cep131 was shown through siRNA knockdown and genetic deletion, in the context of MEFs, to have different phenotypes. In siRNA knockdown, cilia formation was reported to be reduced (Graser et al., 2007; Hall.E, Keighren M., Ford M. et al, 2013). Although male mice were shown to be infertile, a genetic deletion of Azi1 showed that it was not absolutely necessary since the phenotype of cilia formation was unaffected. This is likely due to the activation of compensatory mechanisms during development in the context of a genetic deletion (Graser et al., 2007; Hall.E, Keighren M., Ford M. et al, 2013). In a similar way, an SLK siRNA knockdown shows reduced cell proliferation, however the deletion of SLK had no effect. One possibility is that alternative pathways have been activated, rescuing the proliferation phenotype. An acute siRNA knockdown could also not give the cells enough time to adapt or compensate in this context. As shown previously, a kinase mutant version of SLK has been shown to be embryonic lethal (Al-Zahrani, K. N., Sekhon, P., Tessier et al, 2014). Therefore, the genetic deletion of SLK and expansion of those cells could have also selected for mutants that can grow without SLK.

#### **4.2 SLK is not required for the migration of Mouse Embryonic Fibroblasts**

Previous knockdown studies in mouse fibroblasts showed that SLK is an important regulator of cell migration (Quizi, 2013). SLK has been shown to promote focal adhesion turnover by directly phosphorylating Paxillin at serine 250. A Paxillin mutant at the S250 SLK phosphorylation site (S250A) showed a two-fold decrease in migration rates. Surprisingly, in

MEFs with a genetic deletion of SLK, no effect on cell migration was observed using scratch wounding assays or Boyden chambers (**Figure 7A, B**). FAK and Paxillin were also recruited to the leading edge of the wound despite the absence of SLK expression (**Figure 9A, B, 10**), suggesting that SLK is not required for the redistribution of other migration components. Knock out of the SLK-related kinase MST1 also showed no impairment of migration in plasma cells (Bagherzadeh Y.S, Witalis M, Meli AP, 2019). This similar phenotype could be due to a compensatory mechanism that is activated early during development, resulting in the absence of an observable phenotype. However, in an acute knock down model, overt phenotypes might be observed due to the lack of compensation, leading to impaired motility (Shmidt T, Hampich F, Ridders M, 2007; Barabási AL, Oltvai ZN, 2004). There are several ways that the cell could potentially compensate for the loss of SLK (El-Brolosy MA, Stainier DYR, 2017). One possibility is that other related kinases that perform a similar function to SLK may have been upregulated. This is illustrated when a genetic knockout of Rpl22, a ribosomal protein involved in translation, caused an enhanced expression of Rpl2211 with no obvious translation problems but subtle phenotypes (O'Leary MN, Schreiber KH, Zhang Y, 2013).

As shown previously, SLK is activated downstream of the activated FAK/Src complex in the context of scratch-wound induced migration (Wagner et al., 2008). SLK recruitment to the leading edge of migrating cells also requires FAK/Src activity and the SLK-binding protein LMO4 (Baron et al., 2015). SLK can then directly phosphorylate Paxillin and promote focal adhesion turnover (Quizzi et al., 2013). Nocodazole treatment and release induces synchronized focal adhesion turnover (Kaverina I., Klemens R.J., J. Victor Small, 1998). This is accompanied by a loss of pFAK-Y397, a marker of focal adhesion breakdown (Wagner et al., 2008). Nocodazole release studies showed a faster disappearance of pFAK-Y397 in SLK-null cells,

suggesting a more rapid turnover (**Figure 8A**). Surprisingly the motility rates were similar. We have previously shown that SLK phosphorylates Paxillin on serine 250, stimulating FAK-dependent focal adhesion turnover (Quizi et al., 2013). Since SLK can directly phosphorylate Paxillin, the rapid reduction of pFAK-Y397 could be in response to the loss of Paxillin S250 phosphorylation, resulting in increased dynamics of the pFAK-Y397. This is counter-intuitive and different from what has been observed in siSLK-transfected cells. One possibility is that the knockdown MEFs could not rapidly compensate for the downregulation of SLK while the knockout MEFs have activated compensatory pathways (El-Brolosy MA, Stainier DYR, 2017). It is possible that those pathways can effectively induce turnover independently of Paxillin S250 phosphorylation. Alternatively, the SLK-related kinase LOK could compensate for Paxillin S250 phosphorylation. This has been observed for other GCK members (Miller, C. J., Lou, H. J., Simpson, C., 2019). Another possible explanation could be the heterogeneity of the MEFs isolated and immortalized for this project compared to one of the standard cells lines (MEF 3T3) used previously (Singhal P., Sassi S., Lan L. et al, 2015).

#### **4.3 The Apoptotic Response is not affected in SLK-deficient MEFs**

When SLK was overexpressed in C2C12 myoblasts, apoptosis was triggered and JNK1 was activated (Sabourin LA, Rudnicki MA, 1999; Yan Y, Tulasne D, Browaeys E, 2007; Al-Zahrani, KN., Baron KD, and Sabourin LA, 2013). SLK was also shown to be cleaved by caspase-3 during apoptosis, releasing the active kinase domain and the ATH region. Other studies have shown that SLK could activate the p38 MAPK pathway through ASK1 (Cybulsky AV, Takano T, Guillemette J et al., 2009; Al-Zahrani, KN., Baron KD, and Sabourin LA, 2013). SLK's role was studied in ischemia-reperfusion within kidney cells and was shown to affect ASK1 pathway and

increase the ER-Stress response (Hao W, Takono T, Guillemette J et al., 2006). To test the effect of SLK deletion on the apoptotic response, Staurosporine, Chelerythrine and etoposide were used on both MEF lines to trigger cell death. In contrast to knockdown studies, there were no differences in the rates of cell death between the two cell lines, suggesting that SLK deletion does not impair apoptosis in MEFs (**Figure 11**). Similar findings have been reported in several other models (El-Brolosy MA, Stainier DYR, 2017). As above, there could be an alternative pathway that compensates for the genetic loss of SLK. There could also be another regulator that needed to be deleted, along with SLK, to notice an observable phenotype. An example of this hypothesis is illustrated when HEK293A cells were CRISPR deleted either with MST1/2 or MAK4K4/6/7 but only showed partly reduction of LATS1/2 in the Hippo pathway (Meng Z., Moroishi T., Mottier-Pavie V. et al., 2015). The Hippo Pathway plays a role in regulating tissue state, the final role a cell plays and how big an organ will be (Meng Z., Moroishi T., Mottier-Pavie V. et al., 2015). When both MST1/2 and MAK4K4/6/7 were deleted, phosphorylation of LATS1/2 and YAP/TAZ were abolished (Meng Z., Moroishi T., Mottier-Pavie V. et al., 2015). Their results show that there was a redundant role between MST1/2 and MAK4K4/6/7 in the phosphorylation of LATS1/2 and YAP/TAZ. Therefore, one possibility is that the genetic deletion of SLK along with another unknown gene could result in a more obvious phenotype as there could be parallel processing in this context (Sabourin LA, Rudnicki MA, 1999; Yan Y, Tulasne D, Browaeys E, 2007; Cybulsky AV, Takano T, Guillemette J et al., 2009; Al-Zahrani, KN., Baron KD, and Sabourin LA, 2013; Meng Z., Moroishi T., Mottier-Pavie V. et al., 2015). Similarly, if SLK is negative regulator of specific pathways, their sustained activation in the absence of SLK could lead to cross-talk and the induction of compensatory mechanisms. Alternatively, SLK function is dispensable in MEFs but critical in other cell types. The

embryonic nature of MEFs might not make them dependent on SLK and differentiation or maturation is required for SLK to take over the functions of a more embryonic protein.

#### **4.4 Future Directions**

Here, we have shown that the deletion of SLK in conditional MEFs did not affect growth, motility or apoptosis. The knockdown of SLK through siRNA was previously shown to impair all those processes. It is then likely that a genetic deletion (and expansion in culture) rather than an acute downregulation through siRNA has led to the activation of compensatory pathways. It would then be of interest to screen our cell lines for differentially expressed genes using arrays or RNAseq. Mass spectrometry could also be used to identify global changes in phosphorylated peptides in an effort to identify compensatory pathways. Furthermore, it would be helpful to identify more interacting partners and substrates through immunoprecipitation, mass spectrometry and global kinase assays. Candidate proteins could be knocked down or re-expressed in a genetically deleted SLK context in an attempt to identify proteins or pathways that can compensate for the loss of SLK. Those tagged proteins could also be tested in MEFs that express the gene trap version of SLK (obtained by mating SLK heterozygous mice due to its lethality). A focus for candidates involved in growth, motility and cell death could unravel SLK compensatory pathways in different contexts.



## **4.5 Physiological Relevance**

Due to its potential role in growth and development, understanding the many functions of SLK is of major interest (Yi-Hong Zhang, Karri Hume, Robert Cadonic, et al., 2002).

Specifically, SLK has been shown to play a role in key processes such as proliferation, apoptosis and migration in several contexts (Al-Zahrani, KN., Baron KD, and Sabourin LA, 2013).

Currently, several SLK-deficient cell lines have been generated in the Sabourin lab, providing an opportunity to test the role of SLK in several contexts such as neuronal and muscle development (Yi-Hong Zhang, Karri Hume, Robert Cadonic, et al., 2002). We have shown that a genetic deletion of SLK affects focal adhesion dynamics in MEFs. However, whether this is the case in other cellular contexts remains to be investigated. Movement, morphogenesis, ECM interaction and cell division are all important processes that require focal adhesion signaling (K.

Chinthalapudi, E. S. Rangarajan, Tina Izard, 2018). Therefore, a better understanding of the SLK-dependent pathways may unravel new therapeutic targets for the modulation of those processes in disease contexts.

## **5. Conclusion**

Current literature has mentioned potential compensation mechanisms that occur with genetic knockouts when compared to transient knockdowns as a way to explain the observed phenotypes (Liang H., Wen-Hsiung Li., 2009; El-Brolosy MA, Stainier DYR, 2017). In this project, in contrast to siRNA knockdowns, the genetic deletion of SLK did not affect cell growth, motility or cell death. This is likely due to the activation of alternate pathways in SLK-deficient cells. SLK has been identified more than 20 years ago and several studies have highlighted its

importance in many cell types. Due to recent advances in CRISPR technology, SLK can now be genetically deleted in several cellular contexts. The existence of multiple cell lines and in vitro models makes it possible to identify specific pathways that involve SLK. The discovery of those pathways might lead to the identification of disease genes linked to SLK signaling. The development of SLK inhibitors or modulators could then be useful in the treatment of developmental defects and cancer.

## **6. Appendix I – Validate the putative interaction between SLK and RASSF1A**

This project was pursued due to the possibility of RASSF1A being a binding or activating partner of SLK due to their interplay in similar processes such as proliferation, migration and apoptosis. Both RASSF1A and SLK have a domain known as the SARAH domain which plays a role in apoptosis. It was thought that these proteins might potentially bind through their SARAH domains, however there was only binding in the binding assay but not within the Melanoma Cell lines. There might be a specific event that could cause these proteins to interact however it is currently unknown.

### **6.1 Introduction to Melanoma**

According to the Canadian Cancer Society's Advisory, approximately 7640 people will be diagnosed with melanoma in 2019 (Canadian Cancer Society, 2017). Melanomas generally occur through genetic mutations in pigment producing cells, the melanocytes (Sullivan, R. J., 2015). Melanocyte development is regulated by a multitude of transcription factors and receptors, of which SOX10, MITF and the receptor tyrosine kinase c-KIT are the most important (Tudrej K., Czepielewska E., Wojciechowska M.K., 2016). Melanoma initiation and progression can be affected by genetic and environmental factors (Sullivan, R. J., 2015). In hereditary melanoma, mutations in genes that modulate the cell cycle such as cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase 4 (CDK4) are quite frequent (Sullivan, R. J., 2015). Environmental factors play a role and mostly consists in excessive sun exposure. There are two particular pathways that are commonly affected in melanoma, which are the MAPK and PI3K pathways (Sullivan, R. J., 2015). In melanomas, mutations in the BRAF proto-oncogene (the v-raf murine sarcoma viral oncogene homolog B1) is observed in 50-60% of cases (Perna D., Karreth F., Rust A. et al., 2014). BRAF is a serine/threonine kinase that is highly expressed

in melanocytes (Sullivan, R. J., 2015). In a normal melanocyte, mitogen-activated protein kinase (MAPK) signaling only occurs when there is a ligand interaction with cell membrane receptors and signaling occurs following the activation of those receptors (e.g. epidermal growth factor receptor (EGFR), Platelet derived growth factor receptor (PDGFR)) (Sullivan, R. J., 2015). MAPK signaling activates the RAS family of G proteins that can then activate the BRAF kinase (Sullivan, R. J., 2015). BRAF can activate the MEK-ERK cascade through direct phosphorylation of MEK. ERK then phosphorylates several other downstream targets critical for cell growth and survival (Sullivan, R. J., 2015). For example, one target that ERK phosphorylates is ELK-1 which can then bind to DNA and drive transcription (Sullivan, R. J., 2015). In malignant melanomas bearing BRAF mutations, the MAPK signaling pathway is constitutively activated (Sullivan, R. J., 2015). About 90% of BRAF mutations consist in a valine to glutamic acid change at codon 600 within exon 15 (V600E). This causes the kinase domain to remain in an active state. Two other proteins are frequently mutated with BRAF in melanomas: phosphatase and tensin homolog (PTEN) and CDKN2A. In 50-60% of melanomas, PTEN either has point mutations, small or complete deletions which affects its ability to negatively regulate phosphoinositide (PI) 3-Kinase (PI3K) (Sullivan, R. J., 2015). This leads to increased AKT activity, promoting growth and survival (Hemmings. B, Restuccia D., 2012). CDKN2A encodes for two tumor suppressor proteins, p16<sup>INK4a</sup> and p14<sup>ARF</sup>, that are involved in the retinoblastoma (Rb) and p53 pathways, respectively (Sullivan, R. J., 2015). CDKN2A is usually inactivated by point mutations in melanoma, leading to a loss of gatekeeper function (inducing cell cycle arrest) of the RB or p53 pathway (Sullivan, R. J., 2015).

### **6.1.1 The RASSF1A tumor suppressor**

Before the year 2000, the 3p21.3 gene region was hypothesized to have potential tumor suppressor activity as many lung cancer mutations mapped to this region. Those cancers also displayed loss of heterozygosity, a hallmark of tumor suppressor mutations (Donninger H., Vos M., Clark G., 2007). The RASSF1A gene was later mapped to 3p21.3 region and shown to contain a domain known as the RAS association (RA) domain (Donninger H., Vos M., Clark G., 2007). Two isoforms are encoded by the RASSF1: RASSF1A and RASSF1C (Donninger H., Vos M., Clark G., 2007). RASSF1A was shown to be inactivated in many tumors due to its promoter region being methylated (Donninger H., Vos M., Clark G., 2007). In human cancer, RASSF1A is inactivated at a high frequency (Donninger H., Vos M., Clark G., 2007).

Hypermethylation of the RASSF1A promoter CpG islands causes reduced expression of RASSF1A mRNA and protein levels in melanoma cells and tumors (Gordon, M., Baksh, S., 2011; Yi M., Yang J., Chen X., et al., 2012). As expected, the RASSF1A isoform of the RASSF1 gene was shown to have tumor suppressor activity (Oh, H. J., 2006). RASSF1A is 340 amino acids long and has several different domains, including an SH3 binding domain, a zinc Finger Domain, a RAS Association Domain and a SARAH (Sav/Rassf/Hpo) domain (Oh, H. J., 2006).

RASSF1A has been shown to also play a role in apoptosis and cell cycle control in melanoma (Gordon, M., Baksh, S., 2011). During programmed cell death of A375 melanoma cells, RASSF1A can activate ASK1 which then targets JNK and p38 MAP kinase (Gordon, M., Baksh, S., 2011). This will eventually lead to the activation of caspase 3 and apoptosis (Gordon, M., Baksh, S., 2011). In the context of melanoma, RASSF1A overexpression has been shown to block cell cycle transition from G1-S (Oh, H. J., 2006). RASSF1A prevents phospho-RB and cyclin D1 proteins from building up within the cell, preventing S phase entry (Oh, H. J., 2006).

RASSF1A has been shown to also modulate MST1 in apoptosis (Bitra A., Sistla S., Mariam J., 2017) through interactions between its SARAH domain and MST1 (Canadian Cancer Society, 2017). This is required for the apoptotic functions of RASSF1A. This supports numerous studies highlighting the disruption apoptosis in melanoma (Broussard L., Howland A., Ryu S. et al., 2018).

## **6.2 Purpose of Research**

### **6.2.1 Rationale and Hypothesis**

A putative interaction between SLK and RASSF1A was identified by immunoprecipitation and mass spectrometry. Extensive literature has highlighted the role of RASSF1A in tumor progression, metastasis and cell death in the context of melanoma. (Gordon, M., Baksh, S., 2011, Oh, H. J., Lee, K. K., Song, S. J. et al, 2006). As SLK plays a potential role in migration and tumor cell signaling (Al-Zahrani, PhD Thesis, 2018), we tested the potential of a direct interaction between RASSF1A and SLK. As SLK knockdown impairs growth and migration, our initial hypothesis was that RASSF1A could regulate SLK kinase activity through direct interaction.

### **6.2.2 Objective(s)**


- To determine if RASSF1A binds directly to SLK *in vitro*.
- To assess complex formation between SLK and RASSF1A in melanoma cells.

## **6.3 Results**


### **6.3.1 SLK does not interact with RASSF1A in a specific manner**

RASSF1A has been shown to also play a role in apoptosis and cell cycle control in melanoma (Gordon, M., Baksh, S., 2011). In this context, RASSF1A overexpression has been shown to block cell cycle transition from G1 to S (Oh, H. J., 2006). The identification of RASSF1A in SLK immunoprecipitates suggests that it binds SLK or that they are part of a complex. To test a potential direct interaction, both proteins were in vitro translated in the presence of 35S-methionine and subjected to in vitro binding assays with GST fusion proteins of the other partner. As seen in **Figure 15A**, all the domains of RASSF1A were capable of interacting with in vitro translated full length Myc-SLK. No binding was observed to a GST control, suggesting that the binding to RASSF1A fragments is not to the GST moiety but occurs through non-specific binding. Similarly, HA-RASSF1A bound to all SLK GST fusions, again supporting that the interactions are non-specific (Figure 15B). To further investigate this, SLK was immunoprecipitated from melanoma cell lines that were wildtype, deficient or re-expressed RASSF1A (**Figure 16**). Immunoprecipitation for SLK and blot back for RASSF1A showed no RASSF1A-specific signal when compared to a control lysate, suggesting that they do not form a complex in vivo (**Figure 16A**). Together these results suggest that the in vitro interactions are non-specific and that SLK and RASSF1A are unlikely to interact in vivo. One possibility is that the “sticky” and disorganized nature of the RASSF1A protein induces a high degree of non-specificity in vitro. As these proteins failed to interact, the project was abandoned.


A.




B.



C.





D.





**Figure 15. The SLK-RASSF1A interaction is non-specific.** (A) GST-SLK constructs used for In vitro binding assays (Quizil JL, Baron K, Al-Zahrani KN, 2013). (B) GST-RASSF1A constructs used for In-vitro binding assays (Gordon, M., Baksh, S., 2011). Numbers represent amino acid positions. In vitro binding assays were conducted with in vitro translated Myc-SLK (C) or HA-RASSF1A (D). The indicated immobilized GST-fusions were prepared in bacteria and incubated with the input amount of 35S-labelled protein at room temperature. Interaction was visualized by running the binding assays on SDS gels and exposure to X-ray film (n=3).



**Figure 16. RASSF1A and SLK do not interact in vivo.** (A) SLK was immunoprecipitated from various melanoma cell lines (YUMM and B16) expressing different levels of RASSF1A or re-expressing RASSF1A (HA-RASSF1A). Immune complexes were subjected to Western blot for SLK. No co-immunoprecipitation was observed. (B) Western blot showing the levels of RASSF1A and SLK in the lines used in panel (A) (n=3).

## **6.4 Discussion**

RASSF1A is frequently deleted in melanoma, suggesting that it is a critical tumor suppressor (Gordon, M., Baksh, S., 2011). Its overexpression also suppresses melanoma growth by blocking the G1 to S transition (Oh, H. J., 2006). SLK has a variety of roles different cellular processes including cell migration, changes of the cytoskeleton and cell death (Wagner et al., 2002; Hao W, Takano T, Guillemette J et al., 2006; Quizil JL, Baron K, Al-Zahrani KN, 2013). My data show that SLK and RASSF1A interact in vitro in a non-specific manner. Supporting this, no interaction was observed in vivo. The non-specific interactions could be due to the isolated system in which the binding assay is conducted. Those conditions do not contain exogenous proteins that could be required for specific interactions or to mediate structural changes in SLK or RASSF1A. Alternatively, their association only occurs under specific conditions or in distinct cell types. One possibility is that this interaction occurs during cell migration or cell death. This could be tested under conditions that stimulate those processes. In addition, the interactions could be transient and difficult to detect. It is also possible that this interaction is lost in melanomas. This could perhaps lead to increased SLK activity and enhanced migration and metastasis. Further studies will be required to test these various possibilities.

## References

- Al-Zahrani, K., & Sabourin, L. A. (2018). The Role of the Ste20-like Kinase in Embryonic Development and Neu-induced Mammary Tumorigenesis. University of Ottawa.
- Al-Zahrani, K. N., Baron, K. D., & Sabourin, L. A. (2013). Ste20-like kinase SLK, at the crossroads: a matter of life and death. *Cell Adh Migr*, 7(1), 1-10. doi:10.4161/cam.22495
- Al-Zahrani, K. N., Sekhon, P., Tessier, D. R., Yockell-Lelievre, J., Pryce, B. R., Baron, K. D., Sabourin, L. A. (2014). Essential role for the SLK protein kinase in embryogenesis and placental tissue development. *Dev Dyn*, 243(5), 640-651.
- Bagherzadeh Yazdchi, S., Witalis, M., Meli, A. P., Leung, J., Li, X., Panneton, V., . . . Suh, W. K. (2019). Hippo Pathway Kinase Mst1 Is Required for Long-Lived Humoral Immunity. *J Immunol*, 202(1), 69-78. doi:10.4049/jimmunol.1701407
- Barabasi, A. L., & Oltvai, Z. N. (2004). Network biology: understanding the cell's functional organization. *Nat Rev Genet*, 5(2), 101-113. doi:10.1038/nrg1272
- Barg, J., et al. 1992. *J. Neurochem.* 59, 1145.
- Baron, K. D., Al-Zahrani, K., Conway, J., Labreche, C., Storbeck, C. J., Visvader, J. E., & Sabourin, L. A. (2015). Recruitment and activation of SLK at the leading edge of migrating cells requires Src family kinase activity and the LIM-only protein 4. *Biochim Biophys Acta*, 1853(7), 1683-1692. doi:10.1016/j.bbamcr.2015.04.003
- Bershadsky A, C. A., Becker E, Lyubimova A, Geiger B. (1996). Involvement of microtubules in the control of adhesion-dependent signal transduction. *Current Biology*, 6(10), 1279-1289.
- Bihler, I., & Cybulsky, R. (1973). Sugar transport at the basal and lateral aspect of the small intestinal cell. *Biochim Biophys Acta*, 298(2), 429-436.
- Bitra, A., Sistla, S., Mariam, J., Malvi, H., & Anand, R. (2017). Rassf Proteins as Modulators of Mst1 Kinase Activity. *Sci Rep*, 7, 45020. doi:10.1038/srep45020
- Bolós, V., Gasent, J. M., Lopez-Tarruella, S., & Grande, E. (2010). The dual kinase complex FAK-Src as a promising therapeutic target in cancer. *Onco Targets Ther*, 3, 83-97.
- Broussard, L., Howland, A., Ryu, S., Song, K., Norris, D., Armstrong, C. A., & Song, P. I. (2018). Melanoma Cell Death Mechanisms. *Chonnam Med J*, 54(3), 135-142. doi:10.4068/cmj.2018.54.3.135
- Bruce Alberts, A. J., Julian Lewis, Martin Raff, Keith Roberts, and Peter Walter. (2002). *Molecular Biology of the Cell* (Vol. 4th Edition). New York: Garland Science.
- Bunkoczi, G., Salah, E., Filippakopoulos, P., Fedorov, O., Muller, S., Sobott, F., . . . Knapp, S. (2007). Structural and functional characterization of the human protein kinase ASK1. *Structure*, 15(10), 1215-1226. doi:10.1016/j.str.2007.08.011

- Cai, J., Yang, J., & Jones, D. P. (1998). Mitochondrial control of apoptosis: the role of cytochrome c. *Biochim Biophys Acta*, 1366(1-2), 139-149.
- Chaar, Z., O'Reilly, P., Gelman, I., & Sabourin, L. A. (2006). v-Src-dependent down-regulation of the Ste20-like kinase SLK by casein kinase II. *J Biol Chem*, 281(38), 28193-28199. doi:10.1074/jbc.M605665200
- Chinthalapudi, K., Rangarajan, E. S., & Izard, T. (2018). The interaction of talin with the cell membrane is essential for integrin activation and focal adhesion formation. *Proc Natl Acad Sci U S A*, 115(41), 10339-10344. doi:10.1073/pnas.1806275115
- Cohen, J. J. (1991). Programmed cell death in the immune system. *Adv Immunol*, 50, 55-85.
- Conway, J., Al-Zahrani, K. N., Pryce, B. R., Abou-Hamad, J., & Sabourin, L. A. (2017). Transforming growth factor beta-induced epithelial to mesenchymal transition requires the Ste20-like kinase SLK independently of its catalytic activity. *Oncotarget*, 8(58), 98745-98756. doi:10.18632/oncotarget.21928
- Conway, J., & Sabourin, L. (2016). A Novel Role for SLK in Transforming Growth Factor-Beta-Mediated Epithelial-to-Mesenchymal Transition. (M Sc), University of Ottawa, Retrieved from <http://dx.doi.org/10.20381/ruor-656>
- Cybulsky, A. V., Guillemette, J., & Papillon, J. (2016). Ste20-like kinase, SLK, activates the heat shock factor 1 - Hsp70 pathway. *Biochim Biophys Acta*, 1863(9), 2147-2155. doi:10.1016/j.bbamcr.2016.05.015
- Cybulsky, A. V., Guillemette, J., Papillon, J., & Abouelazm, N. T. (2017). Regulation of Ste20-like kinase, SLK, activity: Dimerization and activation segment phosphorylation. *PLoS One*, 12(5), e0177226. doi:10.1371/journal.pone.0177226
- Cybulsky, A. V., Papillon, J., Guillemette, J., Belkina, N., Patino-Lopez, G., & Torban, E. (2018). Ste20-like kinase, SLK, a novel mediator of podocyte integrity. *Am J Physiol Renal Physiol*, 315(1), F186-F198. doi:10.1152/ajprenal.00238.2017
- Cybulsky, A. V., Takano, T., Guillemette, J., Papillon, J., Volpini, R. A., & Di Battista, J. A. (2009). The Ste20-like kinase SLK promotes p53 transactivation and apoptosis. *Am J Physiol Renal Physiol*, 297(4), F971-980. doi:10.1152/ajprenal.00294.2009
- Cybulsky, A. V., Takano, T., Papillon, J., Guillemette, J., Herzenberg, A. M., & Kennedy, C. R. (2010). Podocyte injury and albuminuria in mice with podocyte-specific overexpression of the Ste20-like kinase, SLK. *Am J Pathol*, 177(5), 2290-2299. doi:10.2353/ajpath.2010.100263
- Cybulsky, A. V., Takano, T., Papillon, J., Hao, W., Mancini, A., Di Battista, J. A., & Cybulsky, M. I. (2007). The 3'-untranslated region of the Ste20-like kinase SLK regulates SLK expression. *Am J Physiol Renal Physiol*, 292(2), F845-852. doi:10.1152/ajprenal.00234.2006
- Cybulsky, D. L., Kandel, S. I., Kandel, M., & Gornall, A. G. (1973). Location of histidine residues that react with bromoacetazolamide and N-bromoacetylacetazolamide in human and bovine carbonic anhydrases. *J Biol Chem*, 248(10), 3411-3418.

- Dan, I., Watanabe, N. M., & Kusumi, A. (2001). The Ste20 group kinases as regulators of MAP kinase cascades. *Trends Cell Biol*, 11(5), 220-230. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11316611>.
- Delarosa, S., Guillemette, J., Papillon, J., Han, Y. S., Kristof, A. S., & Cybulsky, A. V. (2011). Activity of the Ste20-like kinase, SLK, is enhanced by homodimerization. *Am J Physiol Renal Physiol*, 301(3), F554-564. doi:10.1152/ajprenal.00062.2011
- Denecker, G., Ovaere, P., Vandenabeele, P., & Declercq, W. (2008). Caspase-14 reveals its secrets. *J Cell Biol*, 180(3), 451-458. doi:10.1083/jcb.200709098
- Donninger, H., Vos, M. D., & Clark, G. J. (2007). The RASSF1A tumor suppressor. *J Cell Sci*, 120(Pt 18), 3163-3172. doi:10.1242/jcs.010389
- Du, C., Fang, M., Li, Y., Li, L., & Wang, X. (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell*, 102(1), 33-42.
- Ekert, P. G., & Vaux, D. L. (1997). Apoptosis and the immune system. *Br Med Bull*, 53(3), 591-603. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9374039>.
- El-Brolosy, M. A., & Stainier, D. Y. R. (2017). Genetic compensation: A phenomenon in search of mechanisms. *PLoS Genet*, 13(7), e1006780. doi:10.1371/journal.pgen.1006780
- Ellinger-Ziegelbauer, H., Karasuyama, H., Yamada, E., Tsujikawa, K., Todokoro, K., & Nishida, E. (2000). Ste20-like kinase (SLK), a regulatory kinase for polo-like kinase (Plk) during the G2/M transition in somatic cells. *Genes Cells*, 5(6), 491-498.
- Elmore, S. (2007). Apoptosis: a review of programmed cell death. *Toxicol Pathol*, 35(4), 495-516. doi:10.1080/01926230701320337
- Fiszer-Kierzkowska, A., Vydra, N., Wysocka-Wycisk, A., Kronekova, Z., Jarzab, M., Lisowska, K. M., & Krawczyk, Z. (2011). Liposome-based DNA carriers may induce cellular stress response and change gene expression pattern in transfected cells. *BMC Mol Biol*, 12, 27. doi:10.1186/1471-2199-12-27
- Garrido, C., Galluzzi, L., Brunet, M., Puig, P. E., Didelot, C., & Kroemer, G. (2006). Mechanisms of cytochrome c release from mitochondria. *Cell Death Differ*, 13(9), 1423-1433. doi:10.1038/sj.cdd.4401950
- Geetanjali Rampal, N. K., Tarunpreet Singh Thind, Saroj Arora, Adarsh Pal Vig. (2012). Role of isothiocyanates as anticancer agents and their contributing molecular and cellular mechanisms. *Medicinal Chemistry and Drug Discovery*, 3(2), 79-93.
- Gordon, M., & Baksh, S. (2011). RASSF1A: Not a prototypical Ras effector. *Small GTPases*, 2(3), 148-157. doi:10.4161/sgtp.2.3.16286

- Graves, J. D., Gotoh, Y., Draves, K. E., Ambrose, D., Han, D. K., Wright, M., Krebs, E. G. (1998). Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. *EMBO J*, 17(8), 2224-2234. doi:10.1093/emboj/17.8.2224
- Grimm, S., Stanger, B. Z., & Leder, P. (1996). RIP and FADD: two "death domain"-containing proteins can induce apoptosis by convergent, but dissociable, pathways. *Proc Natl Acad Sci U S A*, 93(20), 10923-10927. doi:10.1073/pnas.93.20.10923
- Guilluy, C., Rolli-Derkinderen, M., Loufrani, L., Bourge, A., Henrion, D., Sabourin, L., . . . Pacaud, P. (2008). Ste20-related kinase SLK phosphorylates Ser188 of RhoA to induce vasodilation in response to angiotensin II Type 2 receptor activation. *Circ Res*, 102(10), 1265-1274. doi:10.1161/CIRCRESAHA.107.164764
- Hall, E. A., Keighren, M., Ford, M. J., Davey, T., Jarman, A. P., Smith, L. B., . . . Mill, P. (2013). Acute versus chronic loss of mammalian Azi1/Cep131 results in distinct ciliary phenotypes. *PLoS Genet*, 9(12), e1003928.
- Hande, K. R. (1998). Etoposide: four decades of development of a topoisomerase II inhibitor. *Eur J Cancer*, 34(10), 1514-1521.
- Hao, W., Takano, T., Guillemette, J., Papillon, J., Ren, G., & Cybulsky, A. V. (2006). Induction of apoptosis by the Ste20-like kinase SLK, a germinal center kinase that activates apoptosis signal-regulating kinase and p38. *J Biol Chem*, 281(6), 3075-3084.
- Harbour, J. W., Luo, R. X., Dei Santi, A., Postigo, A. A., & Dean, D. C. (1999). Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. *Cell*, 98(6), 859-869.
- Hemmings, B. A., & Restuccia, D. F. (2012). PI3K-PKB/Akt pathway. *Cold Spring Harb Perspect Biol*, 4(9), a011189. doi:10.1101/cshperspect.a011189
- Hengartner, M. O. (2000). The biochemistry of apoptosis. *Nature*, 407(6805), 770-776. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11048727>. doi:10.1038/35037710
- Horvitz, H. R. (1999). Genetic control of programmed cell death in the nematode *Caenorhabditis elegans*. *Cancer Res*, 59(7 Suppl), 1701s-1706s.
- Horzum, U., Ozdil, B., & Pesen-Okvur, D. (2014). Step-by-step quantitative analysis of focal adhesions. *MethodsX*, 1, 56-59. doi:10.1016/j.mex.2014.06.004
- Hsu, H., Xiong, J., & Goeddel, D. V. (1995). The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. *Cell*, 81(4), 495-504.
- Hu, S., Snipas, S. J., Vincenz, C., Salvesen, G., & Dixit, V. M. (1998). Caspase-14 is a novel developmentally regulated protease. *J Biol Chem*, 273(45), 29648-29653.
- Igney, F. H., & Krammer, P. H. (2002). Death and anti-death: tumour resistance to apoptosis. *Nat Rev Cancer*, 2(4), 277-288.



- Itoh, S., Kameda, Y., Yamada, E., Tsujikawa, K., Mimura, T., & Kohama, Y. (1997). Molecular cloning and characterization of a novel putative STE20-like kinase in guinea pigs. *Arch Biochem Biophys*, 340(2), 201-207.
- Jaberi, A., Hooker, E., Guillemette, J., Papillon, J., Kristof, A. S., & Cybulsky, A. V. (2015). Identification of Tpr and alpha-actinin-4 as two novel SLK-interacting proteins. *Biochim Biophys Acta*, 1853(10 Pt A), 2539-2552. doi:10.1016/j.bbamcr.2015.06.005
- Jalili, A., Moser, A., Pashenkov, M., Wagner, C., Pathria, G., Borgdorff, V., . . . Wagner, S. N. (2011). Polo-like kinase 1 is a potential therapeutic target in human melanoma. *J Invest Dermatol*, 131(9), 1886-1895. doi:10.1038/jid.2011.136
- Jamil S, Lam I, Majd M, Tsai SH, Duronio V. Etoposide induces cell death via mitochondrial-dependent actions of p53. *Cancer Cell Int*. 2015;15:79. Published 2015 Aug 7. doi:10.1186/s12935-015-0231-z
- Johnson, T. M., Antrobus, R., & Johnson, L. N. (2008). Plk1 activation by Ste20-like kinase (Slk) phosphorylation and polo-box phosphopeptide binding assayed with the substrate translationally controlled tumor protein (TCTP). *Biochemistry*, 47(12), 3688-3696. doi:10.1021/bi702134c
- Kandel, M., Gornall, A. G., Cybulsky, D. L., & Kandel, S. I. (1974). Reaction of bromoacetazolamide with crystals of human carbonic anhydrase C. *Biochem Biophys Res Commun*, 56(3), 568-574.
- Kang, S. J., Wang, S., Kuida, K., & Yuan, J. (2002). Distinct downstream pathways of caspase-11 in regulating apoptosis and cytokine maturation during septic shock response. *Cell Death Differ*, 9(10), 1115-1125. doi:10.1038/sj.cdd.4401087
- Kaverina, I., Krylyshkina, O., & Small, J. V. (1999). Microtubule targeting of substrate contacts promotes their relaxation and dissociation. *J Cell Biol*, 146(5), 1033-1044. doi:10.1083/jcb.146.5.1033
- Kaverina, I., Rottner, K., & Small, J. V. (1998). Targeting, capture, and stabilization of microtubules at early focal adhesions. *J Cell Biol*, 142(1), 181-190. doi:10.1083/jcb.142.1.181
- Kerr, J. F. (2002). History of the events leading to the formulation of the apoptosis concept. *Toxicology*, 181-182, 471-474.
- Kerr, J. F., Wyllie, A. H., & Currie, A. R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer*, 26(4), 239-257.
- Koenig, U., Eckhart, L., & Tschachler, E. (2001). Evidence that caspase-13 is not a human but a bovine gene. *Biochem Biophys Res Commun*, 285(5), 1150-1154. doi:10.1006/bbrc.2001.5315
- Komatsu, S. (2015). Western Blotting Using PVDF Membranes and Its Downstream Applications. *Methods Mol Biol*, 1312, 227-236. doi:10.1007/978-1-4939-2694-7\_24

- Kothakota, S., Azuma, T., Reinhard, C., Klippel, A., Tang, J., Chu, K., . . . Williams, L. T. (1997). Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. *Science*, 278(5336), 294-298.
- Kyriakis, J. M., & Avruch, J. (2012). Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. *Physiol Rev*, 92(2), 689-737. doi:10.1152/physrev.00028.2011
- Longo, P. A., Kavran, J. M., Kim, M. S., & Leahy, D. J. (2013). Transient mammalian cell transfection with polyethylenimine (PEI). *Methods Enzymol*, 529, 227-240. doi:10.1016/B978-0-12-418687-3.00018-5
- Luhovy, A. Y., Jaber, A., Papillon, J., Guillemette, J., & Cybulsky, A. V. (2012). Regulation of the Ste20-like kinase, SLK: involvement of activation segment phosphorylation. *J Biol Chem*, 287(8), 5446-5458. doi:10.1074/jbc.M111.302018
- Malumbres, M., & Barbacid, M. (2001). To cycle or not to cycle: a critical decision in cancer. *Nat Rev Cancer*, 1(3), 222-231. doi:10.1038/35106065
- McIlwain, D. R., Berger, T., & Mak, T. W. (2013). Caspase functions in cell death and disease. *Cold Spring Harb Perspect Biol*, 5(4), a008656. doi:10.1101/cshperspect.a008656
- Miller, C. J., Lou, H. J., Simpson, C., van de Kooij, B., Ha, B. H., Fisher, O. S., . . . Turk, B. E. (2019). Comprehensive profiling of the STE20 kinase family defines features essential for selective substrate targeting and signaling output. *PLoS Biol*, 17(3), e2006540. doi:10.1371/journal.pbio.2006540
- Morales, J., Li, L., Fattah, F. J., Dong, Y., Bey, E. A., Patel, M., . . . Boothman, D. A. (2014). Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. *Crit Rev Eukaryot Gene Expr*, 24(1), 15-28.
- Muradian, K., & Schachtschabel, D. O. (2001). The role of apoptosis in aging and age-related disease: update. *Z Gerontol Geriatr*, 34(6), 441-446.
- Nagano, M., Hoshino, D., Koshikawa, N., Akizawa, T., & Seiki, M. (2012). Turnover of focal adhesions and cancer cell migration. *Int J Cell Biol*, 2012, 310616.
- Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B. A., & Yuan, J. (2000). Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. *Nature*, 403(6765), 98-103.
- Norbury, C. J., & Hickson, I. D. (2001). Cellular responses to DNA damage. *Annu Rev Pharmacol Toxicol*, 41, 367-401.
- Oh, H. J., Lee, K. K., Song, S. J., Jin, M. S., Song, M. S., Lee, J. H., . . . Lim, D. S. (2006). Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. *Cancer Res*, 66(5), 2562-2569.

- O'Leary, M. N., Schreiber, K. H., Zhang, Y., Duc, A. C., Rao, S., Hale, J. S., . . . Kennedy, B. K. (2013). The ribosomal protein Rpl22 controls ribosome composition by directly repressing expression of its own paralog, Rpl22l1. *PLoS Genet*, 9(8), e1003708.
- O'Reilly, P. G., Wagner, S., Franks, D. J., Cailliau, K., Browaeys, E., Dissous, C., & Sabourin, L. A. (2005). The Ste20-like kinase SLK is required for cell cycle progression through G2. *J Biol Chem*, 280(51), 42383-42390.
- Paweletz, N. (2001). Walther Flemming: pioneer of mitosis research. *Nat Rev Mol Cell Biol*, 2(1), 72-75. doi:10.1038/35048077
- Perna, D., Karreth, F. A., Rust, A. G., Perez-Mancera, P. A., Rashid, M., Iorio, F., Adams, D. J. (2015). BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. *Proc Natl Acad Sci U S A*, 112(6), E536-545.
- Pike, A. C., Rellos, P., Niesen, F. H., Turnbull, A., Oliver, A. W., Parker, S. A., . . . Knapp, S. (2008). Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. *EMBO J*, 27(4), 704-714.
- Pryce, B. R., Al-Zahrani, K. N., Dufresne, S., Belkina, N., Labreche, C., Patino-Lopez, G., . . . Sabourin, L. A. (2017). Deletion of the Ste20-like kinase SLK in skeletal muscle results in a progressive myopathy and muscle weakness. *Skelet Muscle*, 7(1), 3.
- Quizi, J. L., Baron, K., Al-Zahrani, K. N., O'Reilly, P., Sriram, R. K., Conway, J., . . . Sabourin, L. A. (2013). SLK-mediated phosphorylation of paxillin is required for focal adhesion turnover and cell migration. *Oncogene*, 32(39), 4656-4663.
- Rai, N. K., Tripathi, K., Sharma, D., & Shukla, V. K. (2005). Apoptosis: a basic physiologic process in wound healing. *Int J Low Extrem Wounds*, 4(3), 138-144.
- Roovers, K., Wagner, S., Storbeck, C. J., O'Reilly, P., Lo, V., Northey, J. J., . . . Sabourin, L. A. (2009). The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility. *Oncogene*, 28(31), 2839-2848.
- Ruegg, U.T. and Burgess, G.M. (1989) *Trends Pharmacol. Sci.* 10, 218–220.
- Sabourin, L. A., Girgis-Gabardo, A., Seale, P., Asakura, A., & Rudnicki, M. A. (1999). Reduced differentiation potential of primary MyoD<sup>-/-</sup> myogenic cells derived from adult skeletal muscle. *J Cell Biol*, 144(4), 631-643.
- Sabourin, L. A., & Rudnicki, M. A. (1999). Induction of apoptosis by SLK, a Ste20-related kinase. *Oncogene*, 18(52), 7566-7575.
- Sabourin, L. A., Tamai, K., Seale, P., Wagner, J., & Rudnicki, M. A. (2000). Caspase 3 cleavage of the Ste20-related kinase SLK releases and activates an apoptosis-inducing kinase domain and an actin-disassembling region. *Mol Cell Biol*, 20(2), 684-696.
- Sakahira, H., Enari, M., & Nagata, S. (1998). Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. *Nature*, 391(6662), 96-99. Retrieved from

- Schafer, K. A. (1998). The cell cycle: a review. *Vet Pathol*, 35(6), 461-478.
- Sierra Delarosa, Andrey V. E. Cybulsky. (2009). Regulation of the Ste20-like kinase, SLK. (M.Sc), McGill University
- Society, C. C. (2017). Canadian Cancer Statistics 2017. Canadian Cancer Society's Advisory Committee on Cancer Statistics.
- Storbeck, C. J., Al-Zahrani, K. N., Sriram, R., Kawesa, S., O'Reilly, P., Daniel, K., . . . Sabourin, L. A. (2013). Distinct roles for Ste20-like kinase SLK in muscle function and regeneration. *Skelet Muscle*, 3(1), 16.
- Storbeck, C. J., Daniel, K., Zhang, Y. H., Lunde, J., Scime, A., Asakura, A., . . . Sabourin, L. A. (2004). Ste20-like kinase SLK displays myofiber type specificity and is involved in C2C12 myoblast differentiation. *Muscle Nerve*, 29(4), 553-564.
- Storbeck, C. J., Wagner, S., O'Reilly, P., McKay, M., Parks, R. J., Westphal, H., & Sabourin, L. A. (2009). The Ldb1 and Ldb2 transcriptional cofactors interact with the Ste20-like kinase SLK and regulate cell migration. *Mol Biol Cell*, 20(19), 4174-4182.
- Sullivan, R. J. (2015). BRAF Targets in Melanoma - Biological Mechanisms, Resistance, and Drug Discovery. 82, 204. doi:10.1007/978-1-4939-2143-0
- Trepap, X., Chen, Z., and Jacobson, K. (2012). Cell Migration. *Comprehensive Physiology* 2(4), 2369-2392.
- Tudrej, K. B., Czepielewska, E., & Kozłowska-Wojciechowska, M. (2017). SOX10-MITF pathway activity in melanoma cells. *Arch Med Sci*, 13(6), 1493-1503.
- van der Walt, N. B., Zakeri, Z., & Cronje, M. J. (2016). The Induction of Apoptosis in A375 Malignant Melanoma Cells by *Sutherlandia frutescens*. *Evid Based Complement Alternat Med*, 2016, 4921067. doi:10.1155/2016/4921067
- van Loo, G., van Gurp, M., Depuydt, B., Srinivasula, S. M., Rodriguez, I., Alnemri, E. S., . . . Vandenamee, P. (2002). The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. *Cell Death Differ*, 9(1), 20-26.
- Wagner, S., Flood, T. A., O'Reilly, P., Hume, K., & Sabourin, L. A. (2002). Association of the Ste20-like kinase (SLK) with the microtubule. Role in Rac1-mediated regulation of actin dynamics during cell adhesion and spreading. *J Biol Chem*, 277(40), 37685-37692.
- Wagner, S., Storbeck, C. J., Roovers, K., Char, Z. Y., Kolodziej, P., McKay, M., & Sabourin, L. A. (2008). FAK/src-family dependent activation of the Ste20-like kinase SLK is required for microtubule-dependent focal adhesion turnover and cell migration. *PLoS One*, 3(4), e1868.
- Wagner, S. M., & Sabourin, L. A. (2009). A novel role for the Ste20 kinase SLK in adhesion signaling and cell migration. *Cell Adh Migr*, 3(2), 182-184. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/19262175>.

- Wajant, H. (2002). The Fas signaling pathway: more than a paradigm. *Science*, 296(5573), 1635-1636. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/12040174>. doi:10.1126/science.1071553
- Watanabe, T., Sekine, S., Naguro, I., Sekine, Y., & Ichijo, H. (2015). Apoptosis Signal-regulating Kinase 1 (ASK1)-p38 Pathway-dependent Cytoplasmic Translocation of the Orphan Nuclear Receptor NR4A2 Is Required for Oxidative Stress-induced Necrosis. *J Biol Chem*, 290(17), 10791-10803.
- Wu, J., Zhang, L., & Wang, X. (2000). Maturation and apoptosis of human oocytes in vitro are age-related. *Fertil Steril*, 74(6), 1137-1141.
- Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. *Nature*, 366(6456), 701-704.
- Yamada, E., Tsujikawa, K., Itoh, S., Kameda, Y., Kohama, Y., & Yamamoto, H. (2000). Molecular cloning and characterization of a novel human STE20-like kinase, hSLK. *Biochim Biophys Acta*, 1495(3), 250-262.
- Yan, Y., Tulasne, D., Browaeys, E., Cailliau, K., Khayath, N., Pierce, R. J., . . . Dissous, C. (2007). Molecular cloning and characterisation of SmSLK, a novel Ste20-like kinase in *Schistosoma mansoni*. *Int J Parasitol*, 37(14), 1539-1550.
- Yi, M., Yang, J., Chen, X., Li, J., Li, X., Wang, L., Xie, H. (2011). RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression. *J Cell Physiol*, 226(9), 2360-2369.
- Young, J. C., Agashe, V. R., Siegers, K., & Hartl, F. U. (2004). Pathways of chaperone-mediated protein folding in the cytosol. *Nat Rev Mol Cell Biol*, 5(10), 781-791.
- Zhang, Y. H., Hume, K., Cadonic, R., Thompson, C., Hakim, A., Staines, W., & Sabourin, L. A. (2002). Expression of the Ste20-like kinase SLK during embryonic development and in the murine adult central nervous system. *Brain Res Dev Brain Res*, 139(2), 205-215.
- Zhang, Z. F., Guo, Y., Zhang, J. B., & Wei, X. H. (2011). Induction of apoptosis by chelerythrine chloride through mitochondrial pathway and Bcl-2 family proteins in human hepatoma SMMC-7721 cell. *Arch Pharm Res*, 34(5), 791-800.